Mitsukuni Suenaga, W U Zhang, Tetsuo Mashima, Marta Schirripa, Shu Cao, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Afsaneh Barzi, Toshiharu Yamaguchi, Heinz-Josef Lenz. Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics Proteomics. 2021.04; 18 (3): 317-324. ( PubMed, DOI )

Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Chiara Cremolini, Sara Lonardi, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Shivani Soni, Afsaneh Barzi, Toshiharu Yamaguchi, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics J. 2021.02; ( PubMed, DOI )

Kazuo Kobayashi, Erika Sugiyama, Eiji Shinozaki, Takeru Wakatsuki, Masataka Tajima, Hiyori Kidokoro, Takeshi Aoyama, Yasuhiro Nakano, Kazuyoshi Kawakami, Koki Hashimoto, Mitsukuni Suenaga, Takashi Ichimura, Mariko Ogura, Keisho Chin, Izuma Nakayama, Akira Ooki, Daisuke Takahari, Wataru Suzuki, Takashi Yokokawa, Yuichi Minowa, Tomoko Hiraoka, Kenichi Suzuki, Hitoshi Sato, Toshihiro Hama, Kensei Yamaguchi. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemother Pharmacol. 2021.02; ( PubMed, DOI )

Takahari Daisuke, Shinozaki Eiji, Wakatsuki Takeru, Ooki Akira, Ozaka Masato, Suzuki Takeshi, Nakayama Izuma, Osumi Hiroki, Kamiimabeppu Daisaku, Sato Taro, Ogura Mariko, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research(和訳中) International Journal of Clinical Oncology. 2021.02; 26 (2): 335-344. ( 医中誌 )

Suenaga M, Cao S, Zhang W, Matsusaka S, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Barzi A, Yamamoto N, Yamaguchi T, Lenz HJ. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenetics and genomics. 2021.01; 31 (1): 10-16. ( PubMed, DOI )

Takahari Daisuke, Shinozaki Eiji, Wakatsuki Takeru, Ooki Akira, Ozaka Masato, Suzuki Takeshi, Nakayama Izuma, Osumi Hiroki, Kamiimabeppu Daisaku, Sato Taro, Ogura Mariko, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2020.10; ( PubMed, DOI )

Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata, Takeru Wakatsuki, Shingo Dan, Hiroyuki Seimiya, Kensei Yamaguchi. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis. 2020.09; ( PubMed, DOI )

Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Dongyun Yang, Chiara Cremolini, Sabina Murgioni, Sara Lonardi, Yan Ning, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Afsaneh Barzi, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz. Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers (Basel). 2020.06; 12 (7): ( PubMed, DOI )

Berger Martin D., Ning Yan, Stintzing Sebastian, Heinemann Volker, Cao Shu, Zhang Wu, Yang Dongyun, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Hanna Diana L., Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials EUROPEAN JOURNAL OF CANCER. 2020.05; 131 89-97. ( PubMed, DOI )

Kitagawa Yusuke, Osumi Hiroki, Shinozaki Eiji, Ota Yumiko, Nakayama Izuma, Suzuki Takeshi, Wakatsuki Takeru, Ogura Mariko, Ooki Akira, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study BMC CANCER. 2020.04; 20 (1): 358. ( PubMed, DOI )

Nakayama Izuma, Takahari Daisuke, Wakatsuki Takeru, Osumi Hiroki, Chin Keisho, Ogura Mariko, Sato Taro, Suzuki Takeshi, Kamiimabeppu Daisaku, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting ESMO OPEN. 2020.03; 5 (2): ( PubMed, DOI )

Suenaga Mitsukuni, Wakatsuki Takeru, Mashima Tetsuo, Ogura Mariko, Ichimura Takashi, Shinozaki Eiji, Nakayama Izuma, Osumi Hiroki, Ota Yumiko, Takahari Daisuke, Chin Keisho, Seimiya Hiroyuki, Yamaguchi Kensei. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study INVESTIGATIONAL NEW DRUGS. 2020.02; 38 (1): 111-119. ( PubMed, DOI )

Ota Yumiko, Takahari Daisuke, Suzuki Takeshi, Osumi Hiroki, Nakayama Izuma, Oki Akira, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2020.02; 85 (2): 265-272. ( PubMed, DOI )

Matsusaka Satoshi, Hanna Diana L., Ning Yan, Yang Dongyun, Cao Shu, Berger Martin D., Miyamoto Yuji, Suenaga Mitsukuni, Dan Shingo, Mashima Tetsuo, Seimiya Hiroyuki, Zhang Wu, Lenz Heinz-Josef. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib CANCER SCIENCE. 2020.02; 111 (2): 441-450. ( PubMed, DOI )

Suenaga Mitsukuni, Mashima Tetsuo, Kawata Naomi, Wakatsuki Takeru, Seimiya Hiroyuki, Yamaguchi Kensei. Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

Suenaga Mitsukuni, Zhang Wu, Mashima Tetsuo, Schirripa Marta, Cao Shu, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Barzi Afsaneh, Lenz Heinz-Josef. Gene polymorphisms of CCL3, CCL4, CCL5, and CCR5 network in metastatic colorectal cancer patients treated with regorafenib JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

Berger Martin D., Zlobec Inti, Cao Shu, Miyamoto Yuji, Suenaga Mitsukuni, Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Zhang Wu, Lugli Alessandro, Lenz Heinz-Josef. Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

Kamiimabeppu Daisaku, Wakatsuki Takeru, Takahari Daisuke, Fukuda Naoki, Osumi Hiroki, Nakayama Izuma, Ogura Mariko, Sato Tarou, Ooki Akira, Shinozaki Eiji, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Treatment efficacy of ramucirumab-based chemotherapy in patients with alpha-fetoprotein producing gastric cancer (AFPGC) JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

Miyamoto Y, Schirripa M, Suenaga M, Cao S, Zhang W, Okazaki S, Berger MD, Matsusaka S, Yang D, Ning Y, Baba H, Loupakis F, Lonardi S, Pietrantonio F, Borelli B, Cremolini C, Yamaguchi T, Lenz HJ. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PloS one. 2020; 15 (9): e0239439. ( PubMed, DOI )

Kozuki R., Shinozaki E., Osumi H., Wakatuki T., Suenaga M., Ogura M., Suzuki T., Nakayama I., Takahari D., Chin K., Nagasaki T., Konishi T., Nagayama S., Fukunaga Y., Ueno M., Yamaguchi K.. A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer ANNALS OF ONCOLOGY. 2019.11; 30

Osumi Hiroki, Shinozaki Eiji, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Takahari Daisuke, Ooki Akira, Suzuki Takeshi, Ota Yumiko, Nakayama Izuma, Chin Keisho, Miki Yoshio, Yamaguchi Kensei. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer INTERNATIONAL JOURNAL OF CANCER. 2019.11; 145 (9): 2488-2495. ( PubMed, DOI )

Konishi Tsuyoshi, Shinozaki Eiji, Murofushi Keiko, Taguchi Senzo, Fukunaga Yosuke, Nagayama Satoshi, Fujimoto Yoshiya, Akiyoshi Takashi, Nagasaki Toshiya, Suenaga Mitsukuni, Chino Akiko, Kawachi Hiroshi, Yamamoto Noriko, Ishikawa Yuichi, Oguchi Masahiko, Ishizuka Naoki, Ueno Masashi, Yamaguchi Kensei. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer ANNALS OF SURGICAL ONCOLOGY. 2019.08; 26 (8): 2507-2513. ( PubMed, DOI )

Suzuki Takeshi, Shinozaki Eiji, Osumi Hiroki, Nakayama Izuma, Ota Yumiko, Ichimura Takashi, Ogura Mariko, Wakatsuki Takeru, Ooki Akira, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2019.08; 84 (2): 307-313. ( PubMed, DOI )

Berger Martin D., Cao Shu, Zlobec Inti, Miyamoto Yuji, Suenaga Mitsukuni, Hanna Diana L., Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Zhang Wu, Lugli Alessandro, Lenz Heinz-Josef. Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Fujisaki Junko, Ishikawa Yuichi, Yamaguchi Kensei, Namikawa Ken, Horiuchi Yusuke. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer GASTRIC CANCER. 2019.05; 22 (3): 518-525. ( PubMed, DOI )

Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Fujisaki Junko, Ishikawa Yuichi, Yamaguchi Kensei, Namikawa Ken, Horiuchi Yusuke. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer (vol 22, pg 518, 2019) GASTRIC CANCER. 2019.05; 22 (3): 526. ( PubMed, DOI )

Suenaga Mitsukuni, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Lenz Heinz-Josef. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients INTERNATIONAL JOURNAL OF CANCER. 2019.05; 144 (10): 2567-2577. ( PubMed, DOI )

Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Fujisaki Junko, Ishikawa Yuichi, Yamaguchi Kensei, Namikawa Ken, Horiuchi Yusuke. HER2陽性進行胃癌患者の内視鏡生検検体を用いて評価した、トラスツズマブの有効性に関する腫瘍内HER2不均一性の臨床的意義(Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer) Gastric Cancer. 2019.05; 22 (3): 518-525. ( 医中誌 )

Nakayama Izuma, Takahari Daisuke, Chin Keisho, Ogura Mariko, Wakatsuki Takeru, Osumi Hiroki, Suzuki Takeshi, Ota Yumiko, Ichimura Takashi, Oki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei. EGJ癌に対する全身化学療法(Systemic chemotherapy for the EGJ tumors) 日本胃癌学会総会記事. 2019.02; 91回 283. ( 医中誌 )

Izawa Yukiko, Ichimura Takashi, Chin Keisho, Shinozaki Eiji, Takahari Daisuke, Suenaga Mitsukuni, Ogura Mariko, Wakatsuki Takeru, Osumi Hiroki, Nakayama Izuma, Mine Shinji, Hiki Naoki, Ishizuka Naoki, Yamaguchi Kensei. Feasibility study of diet counseling (DC) with oral nutritional supplements (ONS) for advanced esophageal and gastric cancer during chemotherapy (CT) or chemoradiotherapy (CRT): First report of ONS compliance from a prospective randomized controlled clinical study (DiCON study). JOURNAL OF CLINICAL ONCOLOGY. 2019.02; 37 (4):

Berger Martin D., Stintzing Sebastian, Heinemann Volker, Cao Shu, Miyamoto Yuji, Suenaga Mitsukuni, Hanna Diana L., Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Zhang Wu, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef. Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE JOURNAL OF CLINICAL ONCOLOGY. 2019.02; 37 (4):

Suenaga Mitsukuni, Cao Shu, Zhang Wu, Matsusaka Satoshi, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Barzi Afsaneh, Ueno Masashi, Lenz Heinz-Josef. Role of enterocyte-specific gene polymorphisms in adjuvant treatment for stage III colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2019.02; 37 (4):

Suenaga Mitsukuni, Stintzing Sebastian, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Soni Shivani, Barzi Afsaneh, Heinemann Volker, Lenz Heinz-Josef. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial EUROPEAN JOURNAL OF CANCER. 2019.01; 107 100-114. ( PubMed, DOI )

Kobayashi Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Aoyama Takeshi, Suzuki Kenichi, Wakatsuki Takeru, Suenaga Mitsukuni, Sato Hitoshi, Sugiyama Erika, Yamaguchi Kensei, Hama Toshihiro. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer ONCOLOGY. 2019; 96 (4): 200-206. ( PubMed, DOI )

Kawakami Kazuyoshi, Wakatsuki Takeru, Soejima Azusa, Kobayashi Kazuo, Yokokawa Takashi, Aoyama Takeshi, Suzuki Kenichi, Suenaga Mitsukuni, Yamaguchi Kensei, Inoue Ayaka, Machida Yoshiaki, Hama Toshihiro. Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer PATIENT PREFERENCE AND ADHERENCE. 2019; 13 1745-1750. ( PubMed, DOI )

Nonomiya Yuma, Yokokawa Takashi, Kawakami Kazuyoshi, Kobayashi Kazuo, Aoyama Takeshi, Takiguchi Tomomi, Sugisaki Takahito, Suzuki Kenichi, Suenaga Mitsukuni, Wakatsuki Takeru, Yamaguchi Kensei, Sugimoto Yoshikazu, Hama Toshihiro. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands ONCOLOGY RESEARCH. 2019; 27 (5): 551-556. ( PubMed, DOI )

Kitagawa Yusuke, Osumi Hiroki, Shinozaki Eiji, Ota Yumiko, Nakayama Izuma, Suzuki Takeshi, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Ooki Akira, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study CANCER MANAGEMENT AND RESEARCH. 2019; 11 5757-5764. ( PubMed, DOI )

Kozuki R., Shinozaki E., Osumi H., Wakatsuki T., Suenaga M., Ichimura T., Ogura M., Suzuki T., Ota Y., Nakayama I., Takahari D., Chin K., Nagasaki T., Akiyoshi T., Konishi T., Fujimoto Y., Nagayama S., Fukunaga Y., Ueno M., Yamaguchi K.. A retrospective analysis of the association between perioperative carcinoembryonic antigen level and prognosis in stage III colorectal cancer ANNALS OF ONCOLOGY. 2018.11; 29

Wakatsuki Takeru, Yamamoto Noriko, Sano Takeshi, Chin Keisho, Kawachi Hiroshi, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Matsushima Tomohiro, Suenaga Mitsukuni, Shinozaki Eiji, Hiki Naoki, Ishikawa Yuichi, Yamaguchi Kensei. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer JOURNAL OF GASTROENTEROLOGY. 2018.11; 53 (11): 1186-1195. ( PubMed, DOI )

Wakatsuki Takeru, Yamamoto Noriko, Sano Takeshi, Chin Keisho, Kawachi Hiroshi, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Matsushima Tomohiro, Suenaga Mitsukuni, Shinozaki Eiji, Hiki Naoki, Ishikawa Yuichi, Yamaguchi Kensei. HER2陽性胃癌患者の腫瘍内HER2 heterogeneityがトラスツズマブの有効性に及ぼす臨床的影響(Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer) Journal of Gastroenterology. 2018.11; 53 (11): 1186-1195. ( 医中誌 )

Suenaga M., Wakatsuki T., Ogura M., Ichimura T., Shinozaki E., Nakayama I., Osumi H., Ota Y., Chin K., Mashima T., Seimiya H., Takahari D., Yamaguchi K.. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study ANNALS OF ONCOLOGY. 2018.10; 29 158.

Osumi H., Shinozaki E., Zembutsu H., Takeda Y., Wakatsuki T., Ichimura T., Ota Y., Nakayama I., Ogura M., Suenaga M., Takahari D., Chin K., Saiura A., Takahashi S., Noda T., Yamaguchi K.. Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis ANNALS OF ONCOLOGY. 2018.10; 29 181.

Berger M. D., Stintzing S., Heinemann V., Cao S., Yang D., Miyamoto Y., Suenaga M., Hanna D. L., Soni S., Puccini A., Tokunaga R., Naseem M., Battaglin F., McSkane M., Zhang W., Lenz H-J.. Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3 ANNALS OF ONCOLOGY. 2018.10; 29

Takahashi R., Wakatsuki T., Yamamoto N., Taguchi S., Shinozaki E., Osumi H., Ogura M., Ichimura T., Takahari D., Suenaga M., Chin K., Oguchi M., Ueno M., Yamaguchi K.. p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan ANNALS OF ONCOLOGY. 2018.10; 29

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Cremolini Chiara, Lonardi Sara, Bergamo Francesca, Ning Yang, Yamamoto Noriko, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel Jr., Barzi Afsaneh, Yamaguchi Toshiharu, Stintzing Sebastian, Heinemann Volker, Loupakis Fotios, Falcone Alfredo, Lenz Heinz-Josef. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer PHARMACOGENOMICS JOURNAL. 2018.09; 18 (5): 623-632. ( PubMed, DOI )

Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kensei. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer CANCER SCIENCE. 2018.08; 109 (8): 2567-2575. ( PubMed, DOI )

Osumi Hiroki, Shinozaki Eiji, Zembutsu Hitoshi, Takeda Yoshinori, Wakatsuki Takeru, Ichimura Takashi, Ota Yumiko, Nakayama Izuma, Ogura Mariko, Suenaga Mitsukuni, Takahari Daisuke, Chin Keisho, Saiura Akio, Yamaguchi Kensei. Clinical relevance of circulating cell-free DNA using amplicon-based next-generation sequencing panel in colorectal cancer patients with liver metastasis CANCER RESEARCH. 2018.07; 78 (13): ( DOI )

Osumi H., Shinozaki E., Chin K., Takahari D., Ogura M., Ichimura T., Wakatsuki T., Ota Y., Nakayama I., Suenaga M., Yamaguchi K.. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract ANNALS OF ONCOLOGY. 2018.06; 29 29.

Osumi H., Takahari D., Chin K., Ogura M., Ichimura T., Wakatsuki T., Nakayama I., Ota Y., Suenaga M., Shinozaki E., Yamaguchi K.. First-line mFOLFOX6 for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake ANNALS OF ONCOLOGY. 2018.06; 29

Osumi H., Shinozaki E., Wakatsuki T., Suenaga M., Ichimura T., Ogura M., Ota Y., Nakayama I., Takahari D., Chin K., Yamaguchi K.. Is the PEG-G-CSF useful as the prevention for the severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab? ANNALS OF ONCOLOGY. 2018.06; 29

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Cremolini Chiara, Antoniotti Carlotta, Borelli Beatrice, Mashima Tetsuo, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel Jr., Barzi Afsaneh, Lonardi Sara, Yamaguchi Toshiharu, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib CLINICAL COLORECTAL CANCER. 2018.06; 17 (2): E395-E414. ( PubMed, DOI )

Suenaga Mitsukuni, Schirripa Marta, Loupakis Fotios, Cao Shu, Zhang Wu, Cremolini Chiara, Lonardi Sara, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Falcone Alfredo, Lenz Heinz-Josef. Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15):

Ushida Y, Shinozaki E, Chin K, Suenaga M, Takahari D, Ozaka M, Ogura M, Ichimura T, Wakatsuki T, Yamaguchi K. Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab. Case reports in oncology. 2018.05; 11 (2): 601-608. ( PubMed, DOI )

Shinozaki Eiji, Tanabe Kazuhiro, Akiyoshi Takashi, Tsuchida Tomohiro, Miyazaki Yuko, Kojima Nozomi, Igarashi Masahiro, Ueno Masashi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Kensei, Nakayama Konosuke, Iijima Sadayo, Yamaguchi Toshiharu. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker BMC CANCER. 2018.04; 18 (1): 406. ( PubMed, DOI )

Suenaga Mitsukuni, Akiyoshi Takashi, Shinozaki Eiji, Fujimoto Yoshiya, Matsusaka Satoshi, Konishi Tsuyoshi, Nagayama Satoshi, Fukunaga Yosuke, Kawakami Kazuyoshi, Yokokawa Takashi, Sugisaki Takahito, Ueno Masashi, Yamaguchi Toshiharu. A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study- ANTICANCER RESEARCH. 2018.03; 38 (3): 1741-1747. ( PubMed, DOI )

Fukuda N, Takahari D, Wakatsuki T, Osumi H, Nakayama I, Matsushima T, Ichimura T, Ogura M, Ozaka M, Suenaga M, Shinozaki E, Chin K, Yamaguchi K. Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. Oncotarget. 2018.03; 9 (20): 15219-15227. ( PubMed, DOI )

Schirripa Marta, Zhang Wu, Yang Dongyun, Cao Shu, Okazaki Satoshi, Loupakis Fotios, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, Alberti Giulia, West Jordan D., Lonardi Sara, Khoukaz Taline, Bergamo Francesca, Battaglin Francesca, Antoniotti Carlotta, Falcone Alfredo, Stintzing Sebastian, Heinemann Volker, Lenz Heinz-Josef. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients PLOS ONE. 2018.03; 13 (3): e0193640. ( PubMed, DOI )

Berger Martin D., Stintzing Sebastian, Heinemann Volker, Cao Shu, Yang Dongyun, Sunakawa Yu, Matsusaka Satoshi, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Hanna Diana L., Soni Shivani, Puccini Alberto, Zhang Wu, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab CLINICAL CANCER RESEARCH. 2018.02; 24 (4): 784-793. ( PubMed, DOI )

Berger Martin D., Zlobec Inti, Yang Dongyun, Cao Shu, Sunakawa Yu, Matsusaka Satoshi, Koelzer Viktor H., Inderbitzin Daniel, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Zhang Wu, Lugli Alessandro, Lenz Heinz-Josef. Association of genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II and III colon cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Takahashi Ryo, Wakatsuki Takeru, Shinozaki Eiji, Taguchi Senzo, Fujimoto Yoshiya, Osumi Hiroki, Ota Yumiko, MATSUSHIMA T. O. M. O. H. I. R. O., Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Oguchi Masahiko, Ueno Masashi, Yamaguchi Kensei. Chemoradiation for the treatment of locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Nagaoka Tomoyuki, Shinozaki Eiji, Watanabe Ryosuke, Ueno Eiko, Ota Yumiko, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Suenaga Mitsukuni, Ichimura Takashi, Takahari Daisuke, Chin Keisho, Yamaguchi Kensei. Clinical significance of morphologic response and tumor shrinkage as predictive factors of Capeox plus bevacizumab in 1st line treatment of metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Ushida Yuta, Shinozaki Eiji, Chin Keisho, Suenaga Mitsukuni, Takahari Daisuke, Ozaka Masato, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, MATSUSHIMA T. O. M. O. H. I. R. O., Osumi Hiroki, Ota Yumiko, Yamaguchi Kensei. Clinical outcomes of anti-EGFR antibody treatment for right-sided colon cancer patients without RAS, BRAF, and PIK3CA mutations in the later line JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Yagi Shusuke, Shinozaki Eiji, Chin Keisho, Suenaga Mitsukuni, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, Ozaka Masato, Nakayama Izuma, MATSUSHIMA T. O. M. O. H. I. R. O., Osumi Hiroki, Yamaguchi Kensei. Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Suenaga Mitsukuni, Mashima Tetsuo, Kawata Naomi, Dan Shingo, Wakatsuki Takeru, Shinozaki Eiji, Ichimura Takashi, Ogura Mariko, Takahari Daisuke, Osumi Hiroki, Ota Yumiko, Chin Keisho, Seimiya Hiroyuki, Yamaguchi Kensei, Yamaguchi Toshiharu. Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Bergamo Francesca, Zagonel Vittorina, Rossini Daniele, Borelli Beatrice, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Barzi Afsaneh, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef. Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Takahari Daisuke, Wakatsuki Takeru, Mashima Tetsuo, Chin Keisho, Ichimura Takashi, Ogura Mariko, Matsushima Tomohiro, Osumi Hiroki, Nakayama Izuma, Ota Yumiko, Shinozaki Eiji, Suenaga Mitsukuni, Kawata Naomi, Horiike Yuki, Seimiya Hiroyuki, Fujita Naoya, Yamaguchi Kensei. Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Cremolini Chiara, Murgioni Sabina, Lonardi Sara, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Barzi Afsaneh, Loupakis Fotios, Falcone Alfredo, Lenz Heinz-Josef. Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Ota Yumiko, Wakatsuki Takeru, Mashima Tetsuo, Takahari Daisuke, Chin Keisho, Ichimura Takashi, Ogura Mariko, Matsushima Tomohiro, Osumi Hiroki, Nakayama Izuma, Shinozaki Eiji, Suenaga Mitsukuni, Kawata Naomi, Horiike Yuki, Seimiya Hiroyuki, Fujita Naoya, Yamaguchi Kensei. Plasma biomarker dynamics following ramucirumab treatment and survival analysis after ramucirumab treatment failure in patients with advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Oguri Tomoyo, Takahari Daisuke, Ota Yumiko, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Yamaguchi Kensei. The clinical analysis of thromboembolism in esophagogastric cancer in Japan: A single institute experience. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

Ning Y., Zhang W., Hanna D. L., Yang D., Okazaki S., Berger M. D., Miyamoto Y., Suenaga M., Schirripa M., El-Khoueiry A., Lenz H-J. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients PHARMACOGENOMICS JOURNAL. 2018.01; 18 (1): 29-34. ( DOI )

Osumi Hiroki, Takahari Daisuke, Chin Keisho, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, Suzuki Takeshi, Ota Yumiko, Nakayama Izuma, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake ONCOTARGETS AND THERAPY. 2018; 11 8301-8307. ( PubMed, DOI )

Nakayama Izuma, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, Osumi Hiroki, Ota Yumiko, Suzuki Takeshi, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei. Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer CANCER MANAGEMENT AND RESEARCH. 2018; 10 5283-5290. ( PubMed, DOI )

Nakayama Izuma, Chin Keisho, Matsushima Tomohiro, Takahari Daisuke, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Wakatsuki Takeru, Ichimura Takashi, Hiroki Osumi, Yamaguchi Kensei. Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2017.12; 22 (6): 1060-1068. ( PubMed, DOI )

Berger M. D., Stintzing S., Heinemann V., Yang D., Cao S., Sunakawa Y., Ning Y., Matsusaka S., Okazaki S., Miyamoto Y., Suenaga M., Schirripa M., Soni S., Zhang W., Falcone A., Loupakis F., Lenz H-J. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials ANNALS OF ONCOLOGY. 2017.11; 28 (11): 2780-2785. ( DOI )

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Dadduzio Vincenzo, Salvatore Lisa, Borelli Beatrice, Pietrantonio Filippo, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel Jr., Barzi Afsaneh, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer EUROPEAN JOURNAL OF CANCER. 2017.11; 86 197-206. ( PubMed, DOI )

Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer. 2017.11; 123 (22): 4506-4514. ( PubMed, DOI )

Okazaki Satoshi, Stintzing Sebastian, Sunakawa Yu, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Matsusaka Satoshi, Berger Martin D., Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, West Jordan D., Gopez Roel, Akihito Tsuji, Ichikawa Wataru, Heinemann Volker, DePaolo R. William, Lenz Heinz-Josef. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer INTERNATIONAL JOURNAL OF CANCER. 2017.09; 141 (6): 1222-1230. ( PubMed, DOI )

Schirripa Marta, Zhang Wu, Heinemann Volker, Cao Shu, Okazaki Satoshi, Yang Dongyun, Loupakis Fotios, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, Gopez Roel F., West Jordan D., Hanna Diana, Barzi Afsaneh, Falcone Alfredo, Stintzing Sebastian, Lenz Heinz-Josef. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial INTERNATIONAL JOURNAL OF CANCER. 2017.07; 141 (2): 383-392. ( PubMed, DOI )

Miyamoto Yuji, Stintzing Sebastian, Heinemann Volker, Zhang Wu, Cao Shu, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Matsusaka Satoshi, Ning Yan, Yang Dongyun, Gopez Roel, Melendez Elizabeth, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Lenz Heinz-Josef. Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Berger Martin D., Yamauchi Shinichi, Cao Shu, Hanna Diana L., Sunakawa Yu, Schirripa Marta, Matsusaka Satoshi, Yang Dongyun, Groshen Susan, Zhang Wu, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Lonardi Sara, Cremolini Chiara, Falcone Alfredo, Heinemann Volker, Loupakis Fotios, Stintzing Sebastian, Lenz Heinz-Josef. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials EUROPEAN JOURNAL OF CANCER. 2017.05; 77 13-20. ( PubMed, DOI )

Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Wakatsuki Takeru, Nakayama Izuma, Matsushima Tomohiro, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Chin Keisho, Nagasaki Toshiya, Konishi Tsuyoshi, Akiyoshi Takashi, Fujimoto Yoshiya, Nagayama Satoshi, Fukunaga Yosuke, Ueno Masashi, Yamaguchi Kensei. Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer PLOS ONE. 2017.05; 12 (5): e0176745. ( PubMed, DOI )

Suenaga Mitsukuni, Cao Shu, Stintzing Sebastian, Zhang Wu, Yang Dongyun, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Gopez Roel, Melendez Elizabeth, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Heinemann Volker, Lenz Heinz-Josef. Genetic polymorphisms of CCL5 and CCR5 to predict efficacy of cetuximab-based treatment in metastatic colorectal cancer patients depending on primary tumor location. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Berger Martin D., Stintzing Sebastian, Yang Dongyun, Cao Shu, Miyamoto Yuji, Suenaga Mitsukuni, Soni Shivani, Gopez Roel, Melendez Elizabeth, Zhang Wu, Heinemann Volker, Lenz Heinz-Josef. Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizurnab Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Miyamoto Yuji, Loupakis Fotios, Zhang Wu, Cao Shu, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Matsusaka Satoshi, Ning Yan, Yang Dongyun, Gopez Roel, Melendez Elizabeth, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Falcone Alfredo, Lenz Heinz-Josef. Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Suenaga M., Schirripa M., Cao S., Zhang W., Yang D., Murgioni S., Rossini D., Marmorino F., Mennitto A., Ning Y., Okazaki S., Berger M. D., Miyamoto Y., Gopez R. Jr., Barzi A., Yamaguchi T., Loupakis F., Lenz H. -J.. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer ANNALS OF ONCOLOGY. 2017.05; 28 (5): 1015-1022. ( DOI )

Suenaga Mitsukuni, Cao Shu, Zhang Wu, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Gopez Roel, Melendez Elizabeth, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Lenz Heinz-Josef. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Fukuda Naoki, Takahari Daisuke, Osumi Hiroki, Matsushima Tomohiro, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Yamaguchi Kensei. Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Wakatsuki Takeru, Shinozaki Eiji, Suenaga Mitsukuni, Nakayama Izuma, Matsushima Tomohiro, Osumi Hiroki, Ichimura Takashi, Ogura Mariko, Takahari Daisuke, Ozaka Masato, Chin Keisho, Yamaguchi Kensei. Associations between regorafenib-induced adverse events (AEs) and efficacy in metastatic colorectal cancer (mCRC). JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Matsushima Tomohiro, Osumi Hiroki, Suenaga Mitsukuni, Ozaka Masato, Shinozaki Eiji, Ishikawa Yuichi, Yamaguchi Kensei. Clinical significance of intratumoral HER2 heterogeneity (IHH) using endoscopic biopsy specimens in patients with HER2-positive gastric cancer (GC) who received T-mab-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Berger Martin D., Stintzing Sebastian, Yang Dongyun, Suenaga Mitsukuni, Miyamoto Yuji, Cao Shu, Soni Shivani, Gopez Roel, Hanna Diana L., Zhang Wu, Heinemann Volker, Lenz Heinz-Josef. Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Cao Shu, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Gopez Roel, Hanna Diana L., Zhang Wu, Lenz Heinz-Josef. Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Osumi Hiroki, Takahari Daisuke, Shinozaki Eiji, Chin Keisho, Ogura Mariko, Nakayama Izuma, Matsushima Tomohiro, Wakatsuki Takeru, Ichimura Takashi, Suenaga Mitsukuni, Yamaguchi Kensei. Comparison of early tumor shrinkage between oxaliplatin plus S-1 and cisplatin plus S-1 in first-line chemotherapy with advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Salvatore Lisa, Lonardi Sara, Moretto Roberto, Borelli Beatrice, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Wakatsuki Takeru, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef. Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Takahari Daisuke, Wakatsuki Takeru, Mashima Tetsuo, Ichimura Takashi, Chin Keisho, Ogura Mariko, Nakayama Izuma, Matsushima Tomohiro, Osumi Hiroki, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Seimiya Hiroyuki, Fujita Naoya, Yamaguchi Kensei. Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer: Preliminary results. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Kawakami Kazuyoshi, Suenaga Mitsukuni, Soejima Azusa, Sugita Kazuo, Yokokawa Takashi, Suzuki Kenichi, Inoue Ayaka, Machida Yohiaki, Wakatsuki Takeru, Yamaguchi Kensei, Hama Toshihiro. Self-reported adherence to regorafenib for metastatic colorectal cancer: A retrospective cohort study. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Marmorino Federica, Bergamo Francesca, Antoniotti Carlotta, Rossini Daniele, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Mashima Tetsuo, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef. Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Nagaoka Tomoyuki, Wakatsuki Takeru, Shinozaki Eiji, Nakayama Izuma, Suenaga Mitsukuni, Fukuda Naoki, Osumi Hiroki, Matsushima Tomohiro, Ichimura Takashi, Ogura Mariko, Ozaka Masato, Takahari Daisuke, Chin Keisho, Yamaguchi Kensei. Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Miyamoto Yuji, Stintzing Sebastian, Zhang Wu, Cao Shu, Ning Yan, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Matsusaka Satoshi, Yang Dongyun, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Heinemann Volker, Lenz Heinz-Josef. Polymorphisms in adipokine-related genes to predict treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

Nakayama Izuma, Shinozaki Eiji, Matsushima Tomohiro, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Ozaka Masato, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Kensei. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients BMC CANCER. 2017.01; 17 (1): 38. ( PubMed, DOI )

Kawakami Kazuyoshi, Yokokawa Takashi, Kobayashi Kazuo, Sugisaki Takahito, Suzuki Kenichi, Suenaga Mitsukuni, Yamaguchi Kensei, Inoue Ayaka, Machida Yoshiaki, Yamaguchi Toshiharu, Hama Toshihiro. Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer ONCOLOGY RESEARCH. 2017; 25 (9): 1625-1631. ( PubMed, DOI )

Okazaki S., Loupakis F., Schirripa M., Cao S., Zhang W., Yang D., Ning Y., Berger M. D., Miyamoto Y., Suenaga M., Gopez R., Borelli B. B., Cremolini C., Falcone A., Lonardi S., Salvatore L., Uetake H., Kawano T., Helentjaris T., Lenz H-J.. Tandemrepeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer ANNALS OF ONCOLOGY. 2016.10; 27 ( DOI )

Berger Martin D., Yang Dongyun, Sunakawa Yu, Zhang Wu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Lenz Annika Medea, Bohanes Pierre, Barzi Afsaneh, Figueiredo Jane C., Hanna Diana L., Lenz Heinz-Josef. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012 ONCOTARGET. 2016.08; 7 (33): 53668-53678. ( PubMed, DOI )

Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Konishi Tsuyoshi, Akiyoshi Takashi, Fujimoto Yoshiya, Nagayama Satoshi, Fukunaga Yosuke, Ueno Masashi, Mise Yoshihiro, Ishizawa Takeaki, Inoue Yosuke, Takahashi Yu, Saiura Akio, Uehara Hirohumi, Mun Mingyon, Okumura Sakae, Mizunuma Nobuyuki, Miki Yoshio, Yamaguchi Toshiharu. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy INTERNATIONAL JOURNAL OF CANCER. 2016.08; 139 (4): 803-811. ( PubMed, DOI )

Okazaki Satoshi, Loupakis Fotios, Stintzing Sebastian, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Sunakawa Yu, Stremitzer Stefan, Matsusaka Satoshi, Berger Martin D., Parekh Anish, West Jordan D., Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Cremolini Chiara, Falcone Alfredo, Heinemann Volker, DePaolo R. William, Lenz Heinz-Josef. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab MOLECULAR CANCER THERAPEUTICS. 2016.07; 15 (7): 1740-1745. ( PubMed, DOI )

Osumi H., Shinozaki E., Suenaga M., Matsusaka S., Nakayama I., Wakatsuki T., Ogura M., Ozaka M., Takashi I., Takahari D., Chin K., Mizunuma N., Yamaguchi K.. Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer ANNALS OF ONCOLOGY. 2016.06; 27 16.

Suenaga Mitsukuni, Mashima Tetsuo, Kawata Naomi, Wakatsuki Takeru, Horiike Yuki, Matsusaka Satoshi, Dan Shingo, Shinozaki Eiji, Seimiya Hiroyuki, Mizunuma Nobuyuki, Yamaguchi Kensei, Yamaguchi Toshiharu. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer ONCOTARGET. 2016.06; 7 (23): 34811-34823. ( PubMed, DOI )

Matsusaka Satoshi, Ning Yan, Yang Dongyun, Zhang Wu, Hanna Diana L., Cao Shu, Suenaga Mitsukuni, Okazaki Satoshi, Berger Martin D., Lenz Heinz-Josef. Epidermal growth factor receptor mRNA expression in circulating tumor cells as a potential mechanism of molecular escape from regorafenib therapy. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Schirripa Marta, Yang Dongyun, Loupakis Fotios, Antoniotti Carlotta, Cremolini Chiara, Cao Shu, Okazaki Satoshi, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, Moretto Roberto, Bergamo Francesca, Battaglin Francesca, Lonardi Sara, Gopez Roel, West Jordan David, Zhang Wu, Falcone Alfredo, Lenz Heinz-Josef. Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Schirripa Marta, Zhang Wu, Yang Dongyun, Cao Shu, Okazaki Satoshi, Loupakis Fotios, Berger Martin D., Van Ning, Barzit Afsaneh, Miyamoto Yuji, Suenaga Mitsukuni, Gopez Roel, West Jordan David, Hanna Diana L., Lonardi Sara, Bergamo Francesca, Cremolini Chiara, Falcone Alfredo, Lenz Heinz-Josef. NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Sunakawa Yu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, West Jordan David, Hanna Diana L., Barzi Afsaneh, Zhang Wu, Lenz Heinz-Josef. MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Gopez Roel, Schirripa Marta, Zhang Wu, Cao Shu, Okazaki Satoshi, Yang Dongyun, Loupakis Fotios, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, West Jordan David, Hanna Diana L., Barzi Afsaneh, Falcone Alfredo, Stintzing Sebastian, Heinemann Volker, Lenz Heinz-Josef. IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Cao Shu, Yang Dongyun, Stintzing Sebastian, Loupakis Fotios, Zhang Wu, Ning Yan, Schirripa Marta, Suenaga Mitsukuni, Okazaki Satoshi, Miyamoto Yuji, Barzi Afsaneh, Lenz Heinz-Josef. Identifying predictive SNPs in patients with metastatic colorectal cancer (mCRC) using Random Survival Forests JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Miyamoto Yuji, Stintzing Sebastian, Loupakis Fotios, Zhang Wu, Cao Shu, Ning Yan, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Matsusaka Satoshi, Yang Dongyun, West Jordan David, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Heinemann Volker, Lenz Heinz-Josef. Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Ning Yan, Stintzing Sebastian, Zhang Wu, Yang Dongyun, Hanna Diana L., Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, West Jordan David, Suenaga Mitsukuni, Schirripa Marta, Barzi Afsaneh, Heinemann Volker, Lenz Heinz-Josef. Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Berger Martin D., West Jordan David, Cremolini Chiara, Lonardi Sara, Battaglin Francesca, Ning Yan, Horiike Yuki, Yamamoto Noriko, Okazaki Satoshi, Miyamoto Yuji, Hanna Diana L., Barzi Afsaneh, Loupakis Fotios, Falcone Alfredo, Lenz Heinz-Josef. Genetic variants of Pint to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Zhang Wu, Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Yang Dongyun, Berger Martin D., West Jordan David, Ning Yan, Wakatsuki Takeru, Mashima Tetsuo, Okazaki Satoshi, Miyamoto Yuji, Hanna Diana L., Marmorino Federica, Salvatore Lisa, Moretto Roberto, Borelli Beatrice, Barzi Afsaneh, Loupakis Fotios, Lenz Heinz-Josef. Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Berger Martin D., West Jordan David, Ning Yan, Salvatore Lisa, Rossini Daniele, Antoniotti Carlotta, Inoue Ramu, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Hanna Diana L., Barzi Afsaneh, Loupakis Fotios, Lenz Heinz-Josef. Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

West Jordan David, Zhang Wu, Stintzing Sebastian, Sunakawa Yu, Yang Dongyun, Cao Shu, Ning Yan, Berger Martin D., Gopez Roel, Miyamoto Yuji, Okazaki Satoshi, Suenaga Mitsukuni, Schirripa Marta, Barzi Afsaneh, Hanna Diana L., Tsuji Akihito, Ichikawa Wataru, Heinemann Volker, Lenz Heinz-Josef. Genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3) or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Okazaki Satoshi, Stintzing Sebastian, Sunakawa Yu, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Berger Martin D., West Jordan David, Gopez Roel, Miyamoto Yuji, Suenaga Mitsukuni, Barzi SchirripatAfsaneh, Hanna Diana L., Tsuji Akihito, Ichikawa Wataru, Heinemann Volker, DePaolo William, Lenz Heinz-Josef. Polymorphisms in toll-like receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in patients with metastatic colorectal cancer (mCRC). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Sunakawa Yu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, West Jordan David, Barzi Afsaneh, Hanna Diana L., Zhang Wu, Lenz Heinz-Josef. Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Osumi Hiroki, Yoshio Toshiyuki, Chin Keisho, Ogura Mariko, Kumekawa Yosuke, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Miyamoto Yuji, Morishige Kenjiro, Ishiyama Akiyoshi, Hirasawa Toshiaki, Tsuchida Tomohiro, Yamamoto Yorimasa, Fujisaki Junko, Igarashi Masahiro, Mizunuma Nobuyuki. Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer GASTRIC CANCER. 2016.04; 19 (2): 625-630. ( PubMed, DOI )

Okazaki Satoshi, Stintzing Sebastian, Heinemann Volker, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Matsusaka Satoshi, Berger Martin D., West Jordan D., Miyamoto Yuji, Suenaga Mitsukuni, Lenz Heinz-Josef. Association of TLR9 polymorphism with overall survival in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab enrolled in FIRE3. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

Konishi Tsuyoshi, Shinozaki Eiji, Murofushi Keiko, Ueno Masashi, Fukunaga Yosuke, Nagayama Satoshi, Fujimoto Yoshiya, Akiyoshi Takashi, Suenaga Mitsukuni, Matsusaka Satoshi, Chino Akiko, Kawachi Hiroshi, Yamamoto Noriko, Ishikawa Yuichi, Igarashi Masahiro, Oguchi Masahiko, Mizunuma Nobuyuki, Sano Takeshi, Yamaguchi Toshiharu. Phase II trial of induction mFOLFOX6 plus bevacizumab followed by neoadjuvant S-1-based chemoradiation for MRI-defined poor-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

Shinozaki Eiji, Tanabe Kazuhiro, Akiyoshi Takashi, Tsuchida Tomohiro, Miyazaki Yuko, Kojima Nozomi, Igarashi Masahiro, Ueno Masashi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Nakayama Konosuke, Iijima Sadayo, Yamaguchi Toshiharu. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan as a novel tumor marker for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Sunakawa Yu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, West Jordan David, Zhang Wu, Petasis Nicos, Lenz Heinz-Josef. Serum amyloid a (SAA-1) SNP rs12218 to predict outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Sugisaki Takahito, Takiguchi Tomomi, Aoyama Takeshi, Suzuki Kenichi, Suenaga Mitsukuni, Yamaguchi Kensei, Inoue Ayaka, Machida Yoshiaki, Yamaguchi Toshiharu, Hama Toshihiro. Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study ONCOLOGY. 2016; 91 (4): 224-230. ( PubMed, DOI )

Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Molecular and clinical oncology. 2015.11; 3 (6): 1295-1300. ( PubMed, DOI )

Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Sugisaki Takahito, Takiguchi Tomomi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro. Self-reported adherence with TAS-102 ANNALS OF ONCOLOGY. 2015.11; 26 100.

Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Kumekawa Yosuke, Ogura Mariko, Ozaka Masato, Matsusaka Satoshi, Chin Keisho, Yamamoto Noriko, Mizunuma Nobuyuki. Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? BMC CANCER. 2015.10; 15 760. ( PubMed, DOI )

Yokokawa Takashi, Kawakami Kazuyoshi, Mae Yutaro, Sugita Kazuo, Watanabe Hiroshi, Suzuki Kenichi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro. Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy ANNALS OF PHARMACOTHERAPY. 2015.10; 49 (10): 1120-1124. ( PubMed, DOI )

Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Molecular and clinical oncology. 2015.09; 3 (5): 1053-1057. ( PubMed, DOI )

Wakatsuki T., Suenaga M., Shinozaki E., Nagayama S., Nakayama I., Matsushima T., Ogura M., Ichimura T., Takahari D., Chin K., Kumekawa Y., Sato Y., Fukunaga Y., Ueno M., Mizunuma N., Yamaguchi T.. Genetic variants of UGT1A1 and 1A9 could be associated with Regorafenib induced toxicity in Japanese patients with metastatic colorectal cancer EUROPEAN JOURNAL OF CANCER. 2015.09; 51 S391-S392.

Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Mae Yutaro, Toya Wataru, Hagino Akane, Suzuki Kenichi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro. Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer ANTICANCER RESEARCH. 2015.07; 35 (7): 4059-4062.

Nakayama Izuma, Suenaga Mitsukuni, Wakatsuki Takeru, Ichimura Takashi, Ozaka Masato, Takahari Daisuke, Shinozaki Eiji, Chin Keisho, Ueno Masashi, Mizunuma Nobuyuki, Yamaguchi Toshiharu. Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2015.07; 76 (1): 133-139. ( PubMed, DOI )

Nakayama Izuma, Chin Keisho, Kumekawa Yosuke, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Suenaga Mitsukuni, Ozaka Masato, Shinozaki Eiji, Mizunuma Nobuyuki. Clinical features and outcome of advanced or metastatic gastric cancer in young adult, analysis of 97 cacses JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

Chin Keisho, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Ichimura Takashi, Wakatsuki Takeru, Matsushima Tomohiro, Mizunuma Nobuyuki. Outcome of marked tumor marker increase in patients with advanced gastric cancer during chemotherapy without progression JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

Ichimura Takashi, Chin Keisho, Shinozaki Eiji, Suenaga Mitsukuni, Ogura Mariko, Matsushima Tomohiro, Mizunuma Nobuyuki. The long term survival benefit of salvage chemoradiotherapy for local recurrence of esophageal cancer after curative surgery JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Ogura Mariko, Ozaka Masato, Kumekawa Yosuke, Chin Keisho, Fujimoto Yoshiya, Ueno Masashi, Mizunuma Nobuyuki. The transition of adjuvant chemotherapy for stage III colorectal cancer: A single institute experience in Japan. JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

Suenaga Mitsukuni, Nishina Tomohiro, Mizunuma Nobuyuki, Yasui Hisateru, Ura Takashi, Denda Tadamichi, Ikeda Junichi, Esaki Taito, Nishisaki Hogara, Takano Yoshinao, Sugiyama Yasuyuki, Muro Kei. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802) BMC CANCER. 2015.03; 15 176. ( PubMed, DOI )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study). JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Matsusaka Satoshi, Takahari Daisuke, Ichimura Takashi, Kumekawa Yosuke, Nakayama Izuma, Matsushima Tomohiro, Mizunuma Nobuyuki, Sano Takeshi, Yamaguchi Toshiharu, Ishikawa Yuichi. Association between intratumoral HER2 heterogeneity (IHH) and trastuzumab (T-mab) efficacy in HER2 positive-gastric cancer (GC). JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Kumekawa Yosuke, Wakatsuki Takeru, Osumi Hiroki, Matsushima Tomohiro, Nakayama Izuma, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki. ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Yamada Ikuhiro, Ozaka Masato, Ishii Hiroshi, Sasahira Naoki, Takano Kouichi, Matsuyama Masato, Sasaki Takashi, Saito Kei, Osumi Hiroki, Suenaga Mitsukuni, Igarashi Masahiro. A retrospective study of FOLFOX in the treatment of patients with advanced duodenal adenocarcinoma: A Japanese single-center experience. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Chin Keisho, Yamamoto Yorimasa, Fujisaki Junko, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Mizunuma Nobuyuki. Endoscopic response evaluation of gastric primary lesion for chemotherapy compared to CT in advanced gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Kawakami Kazuyoshi, Yokokawa Takashi, Sugita Kazuo, Hagino Akane, Suzuki Kenichi, Oniyama Sayaka, Kohdo Satoshi, Machida Yohiaki, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Tohiharu, Hama Toshihiro. Patient's self-reported adherence to capecitabine on XELOX as adjuvant therapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Shinozaki Eiji, Miki Yoshio, Ueno Masashi, Igarashi Masahiro, Suenaga Mitsukuni, Chin Keisho, Ozaka Masato, Ogura Mariko, Takahari Daisuke, Ichimura Takashi, Wakatsuki Takeru, Mizunuma Nobuyuki. Phenotypic differences among RAS mutational variations in colorectal cancer (CRC): Analysis of 1,001 patients in single institute. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Nakayama Izuma, Shinozaki Eiji, Wakatsuki Takeru, Kumekawa Yosuke, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Ozaka Masato, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Toshiharu. The significance of EGFR pathway mutations for the efficacy of first line treatment with bevacizumab in metastatic colonrectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer DRUG DESIGN DEVELOPMENT AND THERAPY. 2015; 9 1653-1662. ( PubMed, DOI )

Sato Yasuyoshi, Matsusaka Satoshi, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients ONCOTARGETS AND THERAPY. 2015; 8 3329-3336. ( PubMed, DOI )

Osumi Hiroki, Matsusaka Satoshi, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki. Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab ONCOTARGETS AND THERAPY. 2015; 8 2005-2013. ( PubMed, DOI )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Shinozaki Eiji, Matsusaka Satoshi, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab ONCOTARGETS AND THERAPY. 2015; 8 243-249. ( PubMed, DOI )

Ohhara Yoshihito, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu. Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer ONCOTARGETS AND THERAPY. 2015; 8 529-537. ( PubMed, DOI )

Kawakami Kazuyoshi, Nakamoto Eri, Yokokawa Takashi, Sugita Kazuo, Mae Yutarou, Hagino Akane, Suenaga Mitsukuni, Mizunuma Nobuyuki, Oniyama Sayaka, Machida Yoshiaki, Yamaguchi Toshiharu, Hama Toshihiro. Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis PATIENT PREFERENCE AND ADHERENCE. 2015; 9 561-567. ( PubMed, DOI )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Yamaguchi Toshiharu. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study DRUG DESIGN DEVELOPMENT AND THERAPY. 2015; 9 3099-3108. ( PubMed, DOI )

Suenaga Mitsukuni, Fujimoto Yoshiya, Matsusaka Satoshi, Shinozaki Eiji, Akiyoshi Takashi, Nagayama Satoshi, Fukunaga Yosuke, Oya Masatoshi, Ueno Masashi, Mizunuma Nobuyuki, Yamaguchi Toshiharu. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01) ONCOTARGETS AND THERAPY. 2015; 8 1111-1118. ( PubMed, DOI )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ueno Masashi, Yamaguchi Toshiharu. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2014.12; 10 (4): 322-329. ( PubMed, DOI )

Wakatsuki Takeru, Chin Keisyo, Ogura Mariko, Osaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Kumekawa Yousuke, Nakayama Izuma, Mizunuma Nobuyuki. LOWER CEA AND CA19-9 LEVELS MAY PREDICT LONGER PFS IN PATIENTS WITH HER2 POSITIVE GC TREATED BY T-mab BASED CHEMOTHERAPY ANNALS OF ONCOLOGY. 2014.10; 25 ( DOI )

Kumekawa Yosuke, Chin Keisho, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki. SURVIVAL ANALYSIS OF UNRESECTABLE GASTRIC CANCER PATIENTS JUDGED RESECTABLE BY INITIAL CT ANNALS OF ONCOLOGY. 2014.10; 25 ( DOI )

Suenaga Mitsukuni, Matsuaka Satoshi, Shinozaki Eiji, Ozaka Masato, Chin Keisho, Ogura Mariko, Yamaguchi Toshiharu, Mizunuma Nobuyuki. Analysis of potential circulating angiogenic biomarkers for bevacizumab in patients with Metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

Sato Yasuyoshi, Matsusaka Satoshi, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Chin Kelsho, Mizunuma Nobuyuki. Efficacy of cetuximab-containing chemotherapy with or without bevacizumab in prior chemotherapies JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

Muro Kei, Yamanaka Takeharu, Suenaga Mitsukuni, Nishina Tomohiro, Yasul Hisateru, Ura Takashi, Denda Tadamichi, Ikeda Junichi, Esakl Taito, Nishisaki Hogara, Takano Yoshinao, Kondo Ken, Takeda Koji, Takahashi Yasuo, Endo Kazuya, Sugiyama Yasuyuki. Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

Shinozaki Eiji, Miki Yoshio, Ueno Masashi, Igarashi Masahiro, Suenaga Mitsukuni, Chin Keisho, Ozaka Masato, Ogura Mariko, Yamaguchi Toshiharu, Mizunuma Nobuyuki. Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute. JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

Suenaga Mitsukuni, Fuse Nozomu, Yamaguchi Tatsuro, Yamanaka Yasuhiro, Motomura Shigeki, Matsumoto Hiroshi, Hamamoto Yasuo, Mizunuma Nobuyuki, Doi Toshihiko, Hatake Kiyohiko, Iwasaki Junko, Ohtsu Atsushi. Pharmacokinetics, Safety, and Efficacy of FOLFIRI Plus Bevacizumab in Japanese Colorectal Cancer Patients With UGT1A1 Gene Polymorphisms JOURNAL OF CLINICAL PHARMACOLOGY. 2014.05; 54 (5): 495-502. ( PubMed, DOI )

Wakatsuki Takeru, Chin Keisho, Matsusaka Satoshi, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Nakayama Izuma, Mizunuma Nobuyuki. Exploratory analysis to investigate clinical factors that may influence trastsuzumab efficacy in patients with HER2-positive gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

Osumi Hiroki, Matsusaka Satoshi, Suenaga Mitsukuni, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki. Quantitative analysis of the impact of deepness of response on survival time following patients with metastatic colorectal cancer treated by chemotherapy and anti-EGFR monoclonal antibodies. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Ogura Mariko, Ozaka Masato, Nakayama Izuma, Wakatsuki Takeru, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Toshiharu. SDF-1 and VEGF-C as potential circulating angiogenic biomarkers for bevacizumab in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

Nakayama Izuma, Suenaga Mitsukuni, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Toshiharu. The efficacy of oxaliplatin-based adjuvant chemotherapy for stage IV colorectal cancer after R0 resection. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

Osumi H, Matsusaka S, Shinozaki E, Suenaga M, Mingyon M, Saiura A, Ueno M, Mizunuma N, Yamaguchi T. Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. BMC research notes. 2013.12; 6 508. ( PubMed, DOI )

Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T, Hatake K. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer research. 2013.09; 33 (9): 3905-10. ( PubMed )

Shinozaki Eiji, Yamamoto Noriko, Saiura Akio, Sano Takeshi, Chin Keisho, Ogura Mariko, Matsusaka Satoshi, Suenaga Mitsukuni, Ozaka Masato, Mizunuma Nobuyuki. Concordance of HER2 and its related molecules between primary and paired liver metastatic sites in gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2013.05; 31 (15):

Kumekawa Yosuke, Chin Keisho, Osumi Hiroki, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Sano Takeshi, Mizunuma Nobuyuki. Survival analysis of linitis plastica advanced gastric cancer patients receiving S-1 plus cisplatin. JOURNAL OF CLINICAL ONCOLOGY. 2013.05; 31 (15):

Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study): Reports of interim analysis JOURNAL OF CLINICAL ONCOLOGY. 2013.02; 31 (4):

Ohhara Yoshihito, Matsusaka Satoshi, Shinozaki Eiji, Suenaga Mitsukuni, Mizunuma Nobuyuki, Hatake Kiyohiko, Yamaguchi Toshiharu. Circulating tumor cells as predictive marker in panitumumab after progression of cetuximab in Japanese patients with KRAS wild-type metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2013.02; 31 (4):

Watanabe Toshiyasu, Kijima Sho, Goto Mayu, Koiso Yasuhiro, Kawagoe Naoyuki, Takemoto Ikutaka, Maeda Tadashi, Miyazaki Taito, Kido Hidenori, Honda Yoshiko, Kikuchi Yoshinori, Ogura Mariko, Koike Junichi, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Funahashi Kimihiko, Shimada Nagato, Nakajima Hitoshi, Urita Yosihisa, Shimada Hiedeaki, Kaneko Hironori, Mizunuma Nobuyuki, Sugimoto Motonobu. Hemodialysis improves 5-FU induced hypreanmonemia with depressed level of conciousness with during 5-FU containing regimen for colon cancer JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 2012.12; 27 336-337.

Suenaga M., Matsusaka S., Shinozaki E., Ozaka M., Ogura M., Chin K., Hatake K., Mizunuma N., Yamaguchi T.. A PHASE I/II STUDY OF BI-WEEKLY XELIRI PLUS BEVACIZUMAB FOR PATIENT WITH METASTATIC COLORECTAL CANCER AS SECOND-LINE CHEMOTHERAPY (BIXER STUDY): REPORTS OF INTERIM ANALYSIS OF PHASE II PART ANNALS OF ONCOLOGY. 2012.10; 23 130-131.

Inoue D., Chin K., Ohara K., Takagi K., Ozaka M., Ogura M., Suenaga M., Shinozaki E., Matsusaka S., Mizunuma N., Hatake K.. ABSENCE OF LIVER METASTASIS, LYMPH NODE METASTASIS AND PERITONEAL METASTASIS PREDICT LONGER PROGRESSION FREE SURVIVAL BY S-1 PLUS CISPLATIN TREATMENT IN ADVANCED GASTRIC CANCER ANNALS OF ONCOLOGY. 2012.10; 23 99.

Kawakami K., Nakamoto E., Yokokawa T., Mae Y., Sugita K., Suenaga M., Mizunuma N., Yamaguchi T., Hama T.. COMPLIANCE WITH CAPECITABINE ON XELOX TREATMENT ANNALS OF ONCOLOGY. 2012.10; 23 129.

Matsusaka S., Chin K., Ogur M., Shinozaki E., Suenaga M., Mizunuma N., Sano T., Yamaguchi T., Hatake K.. DETECTION AND HER2 EXPRESSION OF CIRCULATING TUMOR CELLS IN ADVANCED GASTRIC CANCER PATIENTS ANNALS OF ONCOLOGY. 2012.10; 23 118.

Matsusaka S., Kuboki Y., Suenaga M., Shinozaki E., Mizunuma N., Hatake K.. CIRCULATING TUMOR CELLS AS A PROGNOSTIC MARKER IN ADVANCE COLORECTAL CANCER PATIENTS TREATED WITH CETUXIMAB-CONTAINING SALVAGE CHEMOTHERAPY ANNALS OF ONCOLOGY. 2012.09; 23 87.

Tsushima Takahiro, Taguri Masataka, Honma Yoshitaka, Takahashi Hideaki, Ueda Shinya, Nishina Tomohiro, Kawai Hiroki, Kato Shunsuke, Suenaga Mitsukuni, Tamura Fumio, Morita Satoshi, Boku Narikazu. Multicenter Retrospective Study of 132 Patients with Unresectable Small Bowel Adenocarcinoma Treated with Chemotherapy ONCOLOGIST. 2012.09; 17 (9): 1163-1170. ( PubMed, DOI )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Fujimoto Yoshiya, Ueno Masashi, Matsusaka Satoshi, Shinozaki Eiji, Fukunaga Yosuke, Nagayama Satoshi, Yamaguchi Toshiharu. A phase II study of perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01): Report of interim analysis. JOURNAL OF CLINICAL ONCOLOGY. 2012.05; 30 (15):

Matsusaka Satoshi, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki, Sano Takeshi, Yamaguchi Toshiharu, Yamamoto Noriko, Ishikawa Yuichi, Mishima Yuji, Terui Yasuhito, Hatake Kiyohiko. Detection and HER2 expression of circulating tumor cells in advanced gastric cancer patients JOURNAL OF CLINICAL ONCOLOGY. 2012.05; 30 (15):

Ito Yoshinori, Suenaga Mitsukuni, Hatake Kiyohiko, Takahashi Shunji, Yokoyama Masahiro, Onozawa Yusuke, Yamazaki Kentaro, Hironaka Shuichi, Hashigami Kiyoshi, Hasegawa Hirotaka, Takenaka Nobuko, Boku Narikazu. Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2012.04; 42 (4): 278-286. ( PubMed, DOI )

Ito Yoshinori, Suenaga Mitsukuni, Hatake Kiyohiko, Takahashi Shunji, Yokoyama Masahiro, Onozawa Yusuke, Yamazaki Kentaro, Hironaka Shuichi, Hashigami Kiyoshi, Hasegawa Hirotaka, Takenaka Nobuko, Boku Narikazu. 進行固形腫瘍の日本人患者におけるneratinib(HKI-272)の安全性、有効性および薬物動態　第I相用量漸増試験(Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study) Japanese Journal of Clinical Oncology. 2012.04; 42 (4): 278-286. ( 医中誌 )

Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Mizunuma Nobuyuki, Hatake Kiyohiko, Yamaguchi Toshiharu. A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Inoue Dai, Matsusaka Satoshi, Yamamoto Noriko, Suenaga Mitsukuni, Mishima Yuji, Shinozaki Eiji, Terui Yasuhito, Mizunuma Nobuyuki, Ishikawa Yuichi, Hatake Kiyohiko. CD133 status influences in prognosis of patients with metastatic colorectal cancer receiving cetuximab. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Shinozaki Eiji, Ogura Mariko, Ozaka Masato, Takagi Koichi, Yamaguchi Toshiharu, Hatake Kiyohiko. Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Terui Yasuhito, Shinozaki Eiji, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Kawakami Kazuyoshi, Suenaga Mitsukuni, Yokokawa Takashi, Sugita Kazuo, Mae Yutaro, Nakamoto Eri, Imada Hiroshi, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro. Effect of moisturizers on prevention of hand-foot syndrome associated with capecitabine plus oxaliplatin. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Watanabe Toshiyasu, Shinozaki Eiji, Kijima Sho, Ohhara Yoshihito, Kuboki Yasutoshi, Takagi Koichi, Ozaka Masato, Ogura Mariko, Kikuchi Yoshinori, Suenaga Mitsukuni, Chin Keisho, Matsusaka Satoshi, Koike Junichi, Funahashi Kimihiko, Urita Yoshihisa, Mizunuma Nobuyuki, Hatake Kiyohiko, Kaneko Hironori, Sugimoto Motonobu. Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer? JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Ohhara Yoshihito, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. Comparison between the three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Shinozaki Eiji, Yamamoto Noriko, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. How many biopsy fragments will be necessary to assess HER2 status for gastric cancer? JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Ohhara Yoshihito, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. What are the limiting factors related to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer? JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

Itatani Yoshiro, Akiyoshi Takashi, Kuroyanagi Hiroya, Yamakawa Keiko, Noaki Rota, Konishi Tsuyoshi, Fujimoto Yoshiya, Ueno Masashi, Oya Masatoshi, Suenaga Mitsukuni, Yamaguchi Toshiharu. Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case SURGERY TODAY. 2012.01; 42 (1): 75-79. ( PubMed, DOI )

Osako M., Kawazoe Y., Mizunuma N., Gotoh T., Misaka T., Oba M., Shinozaki E., Suenaga M., Matsusaka S., Hatake K.. Cetuximab Treatment for Metastatic Colorectal Cancer With KRAS p.G130 Mutation may Improve Progression-free Survival in Japanese Patients EUROPEAN JOURNAL OF CANCER. 2011.09; 47 S395-S396.

Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2011.09; 68 (3): 763-768. ( PubMed, DOI )

Matsusaka Satoshi, Mishima Yuji, Suenaga Mitsukuni, Terui Yasuhito, Kuniyoshi Ryoko, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating Endothelial Progenitors and CXCR4-Positive Circulating Endothelial Cells Are Predictive Markers for Bevacizumab CANCER. 2011.09; 117 (17): 4026-4032. ( PubMed, DOI )

Suenaga Mitsukuni, Matsusaka Satoshi, Ueno Masashi, Yamamoto Noriko, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients SURGERY TODAY. 2011.08; 41 (8): 1067-1074. ( PubMed, DOI )

Suenaga Mitsukuni, Matsusaka Satoshi, Ueno Masashi, Yamamoto Noriko, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko. 転移性結腸直腸癌患者に対する二次治療としてのFOLFIRI+bevacizumabによる有効性の予測因子(Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients) Surgery Today. 2011.08; 41 (8): 1067-1074. ( 医中誌 )

Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Kuniyoshi Ryoko, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer CANCER SCIENCE. 2011.06; 102 (6): 1188-1192. ( PubMed, DOI )

Suenaga Mitsukuni, Matsusaka Satoshi, Watanabe Toshiyasu, Kuboki Yasutoshi, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki, Ueno Masashi, Yamaguchi Toshiharu, Hatake Kiyohiko. How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer? ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2011.06; 7 (2): 129-135. ( PubMed, DOI )

Matsusaka S., Suenaga M., Mishima Y., Takagi K., Shinozaki E., Terui Y., Mizunuma N., Hatake K.. TIE2-expressing myeloid cells as a predictive marker for bevacizumab-containing chemotherapy in metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2011.05; 29 (15):

Takagi K., Chin K., Oba M., Kuboki Y., Ichimura T., Oto M., Kawazoe Y., Watanabe T., Ozaka M., Ogura M., Suenaga M., Shinozaki E., Matsusaka S., Mizunuma N., Hatake K.. EFFICACY OF PACLITAXEL FOR S-1-REFRACTORY GASTRIC CANCER (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I15.

Matsusaka S., Mizunuma N., Suenaga M., Shinozaki E., Mishima Y., Terui Y., Hatake K.. PREDICTIVE POTENTIAL OF CIRCULATING ENDOTHELIAL CELLS IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING BEVACIZUMAB CONTAINING CHEMOTHERAPY (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I10.

Ozaka M., Ogura M., Matsusaka S., Shinozaki E., Suenaga M., Chin K., Mizunuma N., Hatake K.. THE OPTIMUM TIME FOR SURGERY AFTER RECEIVING IMATINIB: A RETROSPECTIVE ANALYSIS OF GIST PATIENTS ACHIEVING A PARTIAL RESPONSE (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I12.

Suenaga M., Matsusaka S., Watanabe T., Takagi K., Kuboki Y., Ozaka M., Shinozaki E., Chin K., Mizunuma N., Hatake K.. Coagulo-fibrinolytic activity as a predictor of efficacy in bevacizumab-combined chemotherapy in metastatic colorectal cancer patients. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

Suenaga M., Mizunuma N., Matsusaka S., Shinozaki E., Ogura M., Kuboki Y., Watanabe T., Ozaka M., Chin K., Hatake K.. Effect of the addition of bevacizumab to first-line FOLFOX on efficacy, including response rate, progression-free survival, and overall survival, in patients with metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

Suenaga M., Imada H., Nakamoto E., Matsusaka S., Watanabe T., Kawazoe Y., Shinozaki E., Chin K., Mizunuma N., Hatake K.. Optimal use of antihypertensive agents in management of bevacizumab-associated hypertension. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

Tsushima T., Boku N., Honma Y., Takahashi H., Ueda S., Nishina T., Kawai H., Kato S., Suenaga M., Tamura F.. Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

Matsusaka S., Mizunuma N., Suenaga M., Chin K., Shinozaki E., Watanabe T., Kawazoe Y., Kuboki Y., Terui Y., Hatake K.. Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

Matsusaka S., Chin K., Mizunuma N., Ogura M., Suenaga M., Ozaka M., Takagi K., Oba M., Mishima Y., Hatake K.. Use of circulating tumor cells to predict response to chemotherapy in patients with advanced gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

Oba Masaru, Chin Keisho, Kawazoe Yoshimasa, Takagi Koichi, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Hatake Kiyohiko. Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens ONCOLOGY LETTERS. 2011; 2 (2): 247-251. ( PubMed, DOI )

Kuboki Yasutoshi, Mizunuma Nobuyuki, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Chin Keishou, Matsuura Masaaki, Hatake Kiyohiko. Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer ONCOLOGY LETTERS. 2011; 2 (3): 493-498. ( PubMed, DOI )

Oba Masaru, Chin Keisho, Kawazoe Yoshimasa, Takagi Koichi, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Hatake Kiyohiko. Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens ONCOLOGY LETTERS. 2011; 2 (2): 241-245. ( PubMed, DOI )

Matsusaka Satoshi, Mishima Yuji, Mizunuma Nobuyuki, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Ogura Mariko, Osaka Masato, Takagi Koichi, Watanabe Toshiyasu, Nozaki Akira, Oba Masaru, Kawazoe Yoshimasa, Terui Yasuhito, Hatake Kiyohiko. CEP AND CXCR4+CEC ARE PREDICTIVE MARKERS FOR BEVACIZUMAB CONTAINING CHEMOTHERAPY IN MCRC ANNALS OF ONCOLOGY. 2010.11; 21 13.

Watanabe Toshiyasu, Shinozaki Eiji, Asai Hiroaki, Kuboki Yasutoshi, Oto Masafumi, Kawazoe Yoshimasa, Nozaki Akira, Takagi Kouichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko. CETUXIMAB INDUCED ACNE LIKE ERUPTION MIGHT BE MILD IN ELDERLY PATIENTS GROUP ANNALS OF ONCOLOGY. 2010.11; 21 31.

Suenaga Mitsukuni, Mizunuma Nobuyuki, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Kuboki Yasutoshi, Watanabe Toshiyasu, Fujimoto Yoshiya, Ueno Masashi, Kuroyanagi Hiroya, Oya Masatoshi, Yamamoto Noriko, Hatake Kiyohiko. CONTINUATION OF OXALIPLATIN IS A POTENTIAL PREDICTIVE FACTOR IN ADJUVANT FOLFOX FOR STAGE IIIB OR IV COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010.11; 21 30.

Chin Keisho, Yoshimoto Kazuhito, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Suenaga Mitsukuni, Ogura Mariko, Ozaka Masato, Kuboki Yasuhito, Ichimura Takashi, Takagi Koichi, Nozaki Akira, Watanabe Toshiyasu, Hatake Kiyohiko. ENDOSCOPIC EVALUATION OF THE PRIMARY TUMOR CONCERNING OF THE EFFICACY OF CHEMOTHERAPY FOR ADVANCED GASTRIC CANCER ANNALS OF ONCOLOGY. 2010.11; 21 28.

Takagi Koichi, Chin Keisho, Oba Masaru, Kuboki Yasutoshi, Oto Masafumi, Ichimura Takashi, Kawazoe Yoshimasa, Watanabe Toshiyasu, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Mizunuma Nobuyuki, Hatake Kiyohiko. EFFICACY OF PACLITAXEL FOR S-1-REFRACTORY GASTRIC CANCER ANNALS OF ONCOLOGY. 2010.11; 21 28-29.

Ogura Mariko, Matsusaka Satoshi, Kuboki Yasutoshi, Takashi Ichimura, Watanabe Toshiyasu, Takagi Kouichi, Nozaki Akira, Ozaka Masato, Shinozaki Eiji, Suenaga Mitsukuni, Chin Keisyou, Mizunuma Nobuyuki, Hatake Kiyohiko. EFFICACY OF FOLFOX4 REJIMEN FOR METASTATIC COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010.11; 21 30.

Shinozaki Eiji, Mizunuma Nobuyuki, Asai Hiroaki, Watanabe Toshiyasu, Nozaki Akira, Matsusaka Satoshi, Suenaga Mitsukuni, Chin Keisho, Ogura Mariko, Osaka Masato, Kuboki Yasutoshi, Takagi Koichi, Ichimura Takashi, Hatake Kiyohiko. EARLY SERUM MAGNESIUM REDUCTION MAY REPRESENT THE DISEASE CONTROL IN METASTATIC COLORECTAL CANCER TREATED WITH CETUXIMAB ANNALS OF ONCOLOGY. 2010.11; 21 33.

Kawazoe Yoshimasa, Shinozaki Eiji, Hosonaga Mari, Kuboki Yasutoshi, Ichimura Takashi, Watanabe Toshiyasu, Oba Masaru, Takagi Koichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko. FOLFOX COULD INDUCE SPLENOMEGALY, WHICH MIGHT WORSEN THROMBOCYTOPENIA ANNALS OF ONCOLOGY. 2010.11; 21 34.

Mizunuma Nobuyuki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Kuboki Yasutoshi, Nozaki Akira, Takagi Kouichi, Watanabe Toshiyasu, Kawazoe Yoshimasa, Hatake Kiyohiko. METASTATIC COLORECTAL CANCER ADVANCES IN CHEMOTHERAPY; THE REVIEW OF FOR 10 YEARS IN ARIAKE CANCER INSTITUTE ANNALS OF ONCOLOGY. 2010.11; 21 15.

Kuboki Yasutoshi, Shinozaki Eiji, Ichimura Takashi, Ozaka Masato, Oba Masaru, Ogura Mariko, Suenaga Mitukuni, Matusaka Satoshi, Chin Keishou, Mizunuma Nobuyuki, Hatake Kiyohiko. GRADE 2 AND OVER DIGESTIVE TOXICITY IS AN UNFEASIBLE CAUSE OF OUTPATIENT-BASED CDDP IN ADVANCED/RECURRENT GASTRIC CANCER ANNALS OF ONCOLOGY. 2010.11; 21 28.

Asai Hiroaki, Shinozaki Eiji, Mizunuma Nobuyuki, Watanabe Toshiyasu, Nozaki Akira, Kuboki Yasutoshi, Ichimura Takashi, Takagi Koichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsuzaka Satoshi, Chin Keisho, Hatake Kiyohiko. RESPONSE TO CETUXIMAB CONTAINING CHEMOTHERAPY WAS RELATED WITH LONGER TTF:RETROSPECTIVE ANALYSIS OF 72 PATIENTS ANNALS OF ONCOLOGY. 2010.11; 21 33.

Oto Masafumi, Shinozaki Eiji, Kuboki Yasutoshi, Ichimura Taksahi, Watanabe Toshiyasu, Takagi Koichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko, Yamamoto Chiriko. SERUM P53 ANTIBODY IN PATIENTS WITH ESOPAHAGEAL CANCER TREATED WITH CURATIVE CHEMORADIOTERAPY(CRT) IS NOT PREDICTIVE ANNALS OF ONCOLOGY. 2010.11; 21 27-28.

Ozaka Masato, Kuboki Yasutoshi, Ichimura Takashi, Kawazoe Yoshimasa, Watanabe Toshiyasu, Takagi Koichi, Oba Masaru, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko. THE OPTIMAL TIME FOR SURGERY AFTER RECEIVING IMATINIB IN GIST PATIENTS: A RETROSPECTIVE ANALYSIS ANNALS OF ONCOLOGY. 2010.11; 21 18-19.

Nozaki Akira, Shinozaki Eiji, Watanabe Toshiyasu, Takagi Koichi, Ichimura Takashi, Kuboki Yasutoshi, Ozaka Masato, Ogura Mariko, Matsuzaka Satoshi, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko, Matsuura Masaaki, Ushijima Masaru. WHAT HINDERS THE 3RD LINE CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS? ANNALS OF ONCOLOGY. 2010.11; 21 31.

Watanabe Toshiyasu, Suenaga Mitsukuni, Kuboki Yasutoshi, Ichimura Takashi, Kawazoe Yoshimasa, Nozaki Akira, Ooba Masaru, Takagi Kouichi, Ozaka Masato, Ogura Mariko, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko. THE REASON WHY PATIENTS COULD NOT COMBINE BEVACIZUMAB IN METASTATIC COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010.11; 21 15.

Yukisawa S., Fujiwara Y., Yamamoto Y., Ueno T., Matsueda K., Kohno A., Suenaga M.. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients BRITISH JOURNAL OF RADIOLOGY. 2010.10; 83 (994): 850-853. ( DOI )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Kobayashi Kokoro, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Kuboki Yasutoshi, Ichimura Takashi, Ozaka Masato, Ogura Mariko, Fujiwara Yoshimasa, Matsueda Kiyoshi, Konishi Fumio, Hatake Kiyohiko. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab MEDICAL ONCOLOGY. 2010.09; 27 (3): 807-814. ( PubMed, DOI )

Suenaga M., Matsusaka S., Takagi K., Kuboki Y., Watanabe T., Shinozaki E., Chin K., Mizunuma N., Hatake K.. Potential markers predicting bevacizumab efficacy for metastatic colorectal cancer patients. JOURNAL OF CLINICAL ONCOLOGY. 2010.05; 28 (15):

Matsusaka S., Mishima Y., Suenaga M., Takagi K., Shinozaki E., Terui Y., Mizunuma N., Hatake K.. Use of day 4 CEP and baseline CXCR4 plus CEC as predictive markers for bevacizumb in mCRC JOURNAL OF CLINICAL ONCOLOGY. 2010.05; 28 (15):

Matsusaka S, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer science. 2010.04; 101 (4): 1067-71. ( PubMed, DOI )

Matsusaka Satoshi, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Mishima Yuji, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer CANCER SCIENCE. 2010.04; 101 (4): 1067-1071.

Matsusaka Satoshi, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Mishima Yuji, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. 進行胃癌患者の化学療法に対する反応を予測する代理マーカーとしての循環腫瘍細胞(Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer) Cancer Science. 2010.04; 101 (4): 1067-1071. ( 医中誌 )

Fuse N., Suenaga M., Yamaguchi T., Matsumoto H., Mizunuma N., Doi T., Hatake K., Ohtsu A.. FIRST EVALUATION OF THE EFFICACY, SAFETY, AND DRUG-DRUG INTERACTION OF COMBINATION THERAPY OF FOLFIRI AND BEVACIZUMAB IN UGT1A1 GENE POLYMORPHISM OF ADVANCED AND RECURRENT COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010; 21 69.

Suenaga Mitsukuni, Mizunuma Nobuyuki, Shouji Daigo, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Oya Masatoshi, Yamaguchi Toshiharu, Muto Tetsuichiro, Hatake Kiyohiko. Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan (vol 43, pg 842, 2008) JOURNAL OF GASTROENTEROLOGY. 2009.07; 44 (7): 801. ( DOI )

Matsusaka S., Chin K., Mizunuma N., Ogura M., Suenaga M., Shinozaki E., Terui Y., Hatake K.. Circulating tumor cells (CTCs) as a surrogate marker for determining response to chemotherapy in advanced gastric cancer (AGC) JOURNAL OF CLINICAL ONCOLOGY. 2009.05; 27 (15):

Ito Y., Hatake K., Takahashi S., Yokoyama M., Suenaga M., Ota M., Onozawa Y., Yamazaki K., Hironaka S., Boku N.. Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors JOURNAL OF CLINICAL ONCOLOGY. 2009.05; 27 (15):

Suenaga Mitsukuni, Mizunuma Nobuyuki, Chin Keisho, Matsusaka Satoshi, Shinozaki Eiji, Oya Masatoshi, Ueno Masashi, Yamaguchi Toshiharu, Muto Tetsuichiro, Konishi Fumio, Hatake Kiyohiko. Chemotherapy for small-bowel Adenocarcinoma at a single institution SURGERY TODAY. 2009.01; 39 (1): 27-31. ( PubMed, DOI )

Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Chin K, Muto T, Konishi F, Hatake K. Management of allergic reactions to oxaliplatin in colorectal cancer patients. The journal of supportive oncology. 2008.11; 6 (8): 373-8. ( PubMed )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Shouji Daigo, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Oya Masatoshi, Yamaguchi Toshiharu, Muto Tetsuichiro, Hatake Kiyohiko. Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan JOURNAL OF GASTROENTEROLOGY. 2008.11; 43 (11): 842-848. ( PubMed, DOI )

Suenaga Mitsukuni, Mizunuma Nobuyuki, Shouji Daigo, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Oya Masatoshi, Yamaguchi Toshiharu, Muto Tetsuichiro, Hatake Kiyohiko. 日本の単一施設における転移性大腸癌に対するイリノテカン+ボーラス5-フルオロウラシル/L-ロイコボリン変法(Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan) Journal of Gastroenterology. 2008.11; 43 (11): 842-848. ( 医中誌 )

Chin Keisho, Baba Satoshi, Hosaka Hisashi, Ishiyama Akiyoshi, Mizunuma Nobuyuki, Shinozaki Eiji, Suenaga Mitsukuni, Kozuka Takuyo, Seto Yasuyuki, Yamamoto Noriko, Hatake Kiyohiko. Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: Report of 12 cases from single institution experience JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2008.06; 38 (6): 426-431. ( PubMed, DOI )

Chin Keisho, Baba Satoshi, Hosaka Hisashi, Ishiyama Akiyoshi, Mizunuma Nobuyuki, Shinozaki Eiji, Suenaga Mitsukuni, Kozuka Takuyo, Seto Yasuyuki, Yamamoto Noriko, Hatake Kiyohiko. 食道の小細胞癌の治療におけるイリノテカンとシスプラチン　単一施設における経験からの12例の報告(Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience) Japanese Journal of Clinical Oncology. 2008.06; 38 (6): 426-431. ( 医中誌 )

Ozaka M., Shinozaki E., Suenaga M., Matuzaka S., Chin K., Mizunuma N., Hatake K.. A retrospective analysis of patients with complete response (CR) after FOLFOX4: Single institute experience JOURNAL OF CLINICAL ONCOLOGY. 2008.05; 26 (15):

Matsusaka S., Mizunuma N., Matsuda M., Suenaga M., Ogura M., Ichimura T., Shoji D., Oya M., Muto T., Hatake K.. Measures of oxaliplatin-induced neutrotoxicity in 187 patients with FOLFOX4 JOURNAL OF CLINICAL ONCOLOGY. 2007.06; 25 (18):

Suenaga M., Mizunuma N., Chin K., Kuboki Y., Shizozaki E., Yamaguchi T., Muto T., Hatake K.. Preventive approach to allergic reaction to oxaliplatin JOURNAL OF CLINICAL ONCOLOGY. 2007.06; 25 (18):

Suenaga M, Oya M, Ueno M, Yamamoto J, Yamaguchi T, Mizunuma N, Hatake K, Kato Y, Muto T. Anal canal carcinoma with pagetoid spread: Report of a case SURGERY TODAY. 2006.07; 36 (7): 666-669. ( PubMed, DOI )

Sato T, Ohyama S, Kokudo N, Suenaga M, Yamamoto J, Yamaguchi T, Muto T. The repeated hepatectomy for frequent recurrence of hepatic metastasis from gastrointestinal stromal tumor of the stomach. Hepato-gastroenterology. 2004.01; 51 (55): 181-3. ( PubMed )

Sato T, Ohta K, Ohyama S, Suenaga M, Ueno M, Oya M, Yamamoto J, Yamaguchi T, Muto T, Kato Y. Klippel-Trenaunay-Weber syndrome and duodenal hemorrhage. Gastrointestinal endoscopy. 2003.11; 58 (5): 756-7. ( PubMed, DOI )

Suenaga M, Ohta K, Toguchi M, Sato T, Ohyama S, Yamaguchi T, Muto T, Yanagisawa A, Kato Y. Colliding gastric and intestinal phenotype well-differentiated adenocarcinoma of the stomach developing in an area of MALT-type lymphoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2003; 6 (4): 270-6. ( PubMed, DOI )

末永 光邦, 植竹 宏之. 【がん薬物療法中の腹部救急疾患・有害事象に対する対策と治療】化学療法中の消化器関連有害事象に対する治療アプローチ　コロナ禍が医療現場へもたらす負担 日本腹部救急医学会雑誌. 2023.03; 43 (3): 629-635. ( 医中誌 )

末永光邦、植竹宏之. 化学療法中の消化器関連有害事象に対する治療アプローチ～コロナ禍が医療現場へもたらす負担～ 日本腹部救急医学会雑誌. 2023; 43 (3): 1-7.

末永光邦、植竹宏之. 進行・再発大腸癌の薬物療法 メディカル・サイエンス・ダイジェスト. 2022.03; 48 (3): 139-142.

末永 光邦, 植竹 宏之. 【大腸がん診療の最近の進歩】進行・再発大腸癌の薬物療法 Medical Science Digest. 2022.03; 48 (3): 139-142. ( 医中誌 )

Matsumiya Yuriko, Suenaga Mitsukuni, Ishikawa Toshiaki, Hanaoka Marie, Iwata Noriko, Masuda Taiki, Yamauchi Shinichi, Tokunaga Masanori, Kinugasa Yusuke. Clinical significance of <i>Bacteroides fragilis</i> as potential prognostic factor in colorectal cancer patients JOURNAL OF CLINICAL ONCOLOGY. 2022.02; 40 (4): ( DOI )

松宮 由利子, 末永 光邦, 角田 龍太, 岩田 乃理子, 増田 大機, 山内 慎一, 松山 貴俊, 徳永 正則, 石川 敏昭, 絹笠 祐介. 大腸癌術後患者におけるBacteroides fragilisと予後の検討 日本消化器外科学会総会. 2021.07; 76回 P161-7. ( 医中誌 )

高橋 遼, 若槻 尊, 篠崎 英司, 室伏 景子, 藤本 佳也, 大隅 寛木, 松島 知広, 小倉 真理子, 市村 崇, 高張 大亮, 末永 光邦, 陳 勁松, 小口 正彦, 上野 雅資, 山口 研成. 当院における限局性肛門扁平上皮癌に対する化学放射線療法の治療成績 日本癌治療学会学術集会抄録集. 2017.10; 55回 P131-6. ( 医中誌 )

平山 佳愛, 篠崎 英司, 若槻 尊, 市村 崇, 小倉 真理子, 高張 大亮, 末永 光邦, 陳 勁松, 長嵜 寿矢, 秋吉 高志, 小西 毅, 藤本 佳也, 長山 聡, 福永 洋介, 上野 雅資, 山口 研成. 直腸癌に対する術前化学放射線療法および化学療法の病理組織学的治療効果判定 日本消化器外科学会雑誌. 2017.10; 50 (Suppl.2): 380. ( 医中誌 )

末永 光邦. 【最新臨床大腸癌学-基礎研究から臨床応用へ-】大腸癌の治療　化学療法　切除不能進行・再発大腸癌の治療戦略におけるTAS102の位置づけ 日本臨床. 2015.04; 73 (増刊4 最新臨床大腸癌学): 510-514. ( 医中誌 )

川上 和宜, 末永 光邦. 【薬と検査2014　薬物治療&服薬指導プラクティカルガイド】皮膚疾患　手足症候群 薬局. 2014.03; 65 (4): 1571-1578. ( 医中誌 )

末永 光邦. 血管新生阻害剤における抗腫瘍効果の予測因子と耐性獲得因子のバイオマーカー解析 大和証券ヘルス財団研究業績集. 2014.03; (37): 149-154. ( 医中誌 )

中山 厳馬, 末永 光邦. 【がん化学療法看護のいま〜ケアの質を高めるためのエッセンス〜】(第I章)がん化学療法のいま　支持療法のいま がん看護. 2014.02; 19 (2): 114-121. ( 医中誌 )

Osumi H, Shinozaki E, Kumekawa Y, Ogura M, Ozaka M, Suenaga M, Matsusaka S, Chin K, Mizunuma N, Yokoyama M. [Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 2013.11; 40 (11): 1557-60. ( PubMed )

Mukai T, Akiyoshi T, Koga R, Arita J, Saiura A, Ikeda A, Nagasue Y, Oikawa Y, Yamakawa K, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Suenaga M, Mizunuma N, Shinozaki E, Yamamoto C, Yamaguchi T. [A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab]. Gan to kagaku ryoho. Cancer & chemotherapy. 2012.12; 39 (13): 2561-3. ( PubMed )

向井 俊貴, 秋吉 高志, 古賀 倫太郎, 有田 淳一, 齋浦 明夫, 池田 篤志, 永末 裕友, 及川 芳徳, 山川 景子, 小西 毅, 藤本 佳也, 長山 聡, 福長 洋介, 上野 雅資, 末永 光邦, 水沼 信之, 篠崎 英司, 山本 智理子, 山口 俊晴. XELOX+Bevacizumab療法によりPathological Complete Responseを得た肝門部リンパ節転移を伴う横行結腸癌多発肝転移の1切除例 癌と化学療法. 2012.12; 39 (13): 2561-2563. ( 医中誌 )

末永 光邦. 【臨床現場が知りたい大腸がん薬物治療】効果的な治療法の選択　専門医からのアドバイス　有害事象が発現したレジメンを再び用いることは可能か? 臨床腫瘍プラクティス. 2012.11; 8 (4): 369-374. ( 医中誌 )

前 勇太郎, 横川 貴志, 川上 和宜, 八木 奈央, 末永 光邦, 篠崎 英司, 松阪 諭, 水沼 信之, 濱 敏弘. XELOX療法における薬剤師外来の有用性 医療薬学. 2011.11; 37 (11): 611-615. ( 医中誌 )

Asai H, Shinozaki E, Nozaki A, Watanabe T, Suenaga M, Matuzaka S, Chin K, Mizunuma N, Yasukawa M, Hatake K. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2011.08; 38 (8): 1285-91. ( PubMed )

Oya M, Sameshima S, Tagaya N, Takeshita E, Koketsu S, Sugamata Y, Yoshiba H, Ueno M, Fujimoto Y, Suenaga M. [Colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2011.08; 38 (8): 1252-5. ( PubMed )

大矢 雅敏, 鮫島 伸一, 多賀谷 信美, 竹下 恵美子, 纐纈 真一郎, 菅又 嘉剛, 吉羽 秀麿, 上野 雅資, 藤本 佳也, 末永 光邦. 【Marginally Resectable Tumorに対する治療戦略】大腸癌 癌と化学療法. 2011.08; 38 (8): 1252-1255. ( 医中誌 )

朝井 洋晶, 篠崎 英司, 野崎 明, 渡邉 利泰, 末永 光邦, 松阪 諭, 陳 勁松, 水沼 信之, 安川 正貴, 畠 清彦. 切除不能進行再発大腸癌に対する三次治療としてのCetuximab+Irinotecan併用化学療法の治療効果とKRAS遺伝子変異の相関 癌と化学療法. 2011.08; 38 (8): 1285-1291. ( 医中誌 )

中本 恵理, 川上 和宜, 今田 洋司, 式部 さあ里, 杉田 一男, 篠崎 英司, 末永 光邦, 松阪 諭, 水沼 信之, 濱 敏弘. Cetuximab投与後に生じる低マグネシウム血症の発現頻度と発現時期の調査とその対策 医療薬学. 2011.07; 37 (7): 403-409. ( 医中誌 )

Kawazoe Y, Hatake K, Suenaga M, Mizunuma N. [Administration-limiting factor of bevacizumab for patient with metastatic colorectal cancer]. Nihon rinsho. Japanese journal of clinical medicine. 2011.04; 69 Suppl 3 472-6. ( PubMed )

河添 悦昌, 末永 光邦, 畠 清彦, 水沼 信之. 【大腸癌　最新の研究動向】大腸癌の治療戦略　化学療法　大腸癌患者へのbevacizumabの適応選択(投与規定因子) 日本臨床. 2011.04; 69 (増刊3 大腸癌): 472-476. ( 医中誌 )

Mitsuhashi K, Matsusaka S, Mizunuma N, Ichimura T, Ozaka M, Ogura M, Shinozaki E, Suenaga M, Chin K, Fujimoto Y, Saiura A, Yamamoto N, Hatake K. [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection]. Gan to kagaku ryoho. Cancer & chemotherapy. 2010.11; 37 (11): 2203-7. ( PubMed )

Ichimura T, Chin K, Kobayashi K, Osaka M, Kuboki Y, Ogura M, Shinozaki E, Suenaga M, Matsuzaka S, Mizunuma N, Hatake K. [The incidence of gastrointestinal bleeding, thromboembolic events, and gastrointestinal perforation in metastatic or unresectable gastric cancer during chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 2010.11; 37 (11): 2131-6. ( PubMed )

三橋 健次郎, 松阪 諭, 水沼 信之, 市村 崇, 尾阪 将人, 小倉 真理子, 篠崎 英司, 末永 光邦, 陳 勁松, 藤本 佳也, 齋浦 明夫, 山本 智理子, 畠 清彦. Cetuximab療法により完全切除可能となったFOLFOX療法抵抗性・切除不能直腸癌多発肝転移の1症例 癌と化学療法. 2010.11; 37 (11): 2203-2207. ( 医中誌 )

末永 光邦. 【消化器癌・悪性腫瘍の分子標的治療薬を用いた薬物療法】消化器癌・悪性腫瘍の分子標的治療薬の有害事象とその対策 消化器の臨床. 2010.10; 13 (5): 570-577. ( 医中誌 )

末永 光邦. 【消化器がん化学療法看護完全マスターBOOK　分子標的薬と従来型抗がん剤のケア 副作用 治療のしくみがやさしくわかる!】分子標的薬の必須情報と副作用対策　分子標的薬の副作用マネジメント　急性心筋梗塞 消化器外科Nursing. 2010.02; (2010臨時増刊): 190-191. ( 医中誌 )

末永 光邦. 【消化器がん化学療法看護完全マスターBOOK　分子標的薬と従来型抗がん剤のケア 副作用 治療のしくみがやさしくわかる!】分子標的薬の必須情報と副作用対策　分子標的薬の副作用マネジメント　高血圧 消化器外科Nursing. 2010.02; (2010臨時増刊): 182-189. ( 医中誌 )

末永 光邦, 水沼 信之, 畠 清彦. 【大腸癌化学療法の最前線】分子標的薬を使うタイミングとコツ　bevacizumab(アバスチン) Intestine. 2009.11; 13 (6): 611-616. ( 医中誌 )

末永 光邦. わかりやすい臨床試験(No.3)　GCP(good clinical practice) Drug Delivery System. 2009.11; 24 (6): 627-629. ( 医中誌 )

末永 光邦. 【癌治療の現状と展望　標準治療の連携と分子標的薬剤のバイオマーカー】治療薬解説　ベバシズマブ(アバスチン) カレントテラピー. 2009.11; 27 (11): 1046-1052. ( 医中誌 )

吉本 和仁, 陳 勁松, 小倉 真理子, 末永 光邦, 篠崎 英司, 松阪 諭, 水沼 信之, 石山 晃世志, 山本 頼正, 土田 知宏, 藤崎 順子, 星野 惠津夫, 畠 清彦. 【消化管癌の化学・放射線療法の効果判定と問題点】胃癌化学療法における原発巣効果判定　CTでの効果判定と内視鏡検査の意義 胃と腸. 2009.11; 44 (12): 1859-1870. ( 医中誌 )

末永 光邦. 【大腸癌治療の現在　化学療法と外科手術のコンビネーション】大腸癌化学療法の副作用とその対策 Pharma Medica. 2009.11; 27 (11): 35-39. ( 医中誌 )

Yokokawa T, Matsusaka S, Shouji D, Imada H, Nakamoto E, Kamisugi K, Suzuki W, Shirai T, Takahashi G, Kawakami K, Shinozaki E, Suenaga M, Mizunuma N, Hatake K, Hama T. [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2009.08; 129 (8): 949-55. ( PubMed, DOI )

Yokokawa Takashi, Matsusaka Satoshi, Shouji Daigo, Imada Hiroshi, Nakamoto Eri, Kamisugi Kayoko, Suzuki Wataru, Shirai Takeshi, Takahashi Gou, Kawakami Kazuyoshi, Shinozaki Eiji, Suenaga Mitsukuni, Mizunuma Nobuyuki, Hatake Kiyohiko, Hama Toshihiro. Efficacy of Preventive Treatment for Delayed Emesis Induced by FOLFOX4 Chemotherapy YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN. 2009.08; 129 (8): 949-955.

横川 貴志, 松阪 諭, 庄司 大悟, 今田 洋司, 中本 恵理, 神杉 香代子, 鈴木 亘, 白井 健之, 高橋 郷, 川上 和宜, 篠崎 英司, 末永 光邦, 水沼 信之, 畠 清彦, 濱 敏弘. FOLFOX4療法における遅発性悪心・嘔吐に対する予防療法の有効性の検討 薬学雑誌. 2009.08; 129 (8): 949-955. ( 医中誌 )

Shouji D, Matsusaka S, Watanabe C, Suenaga M, Shinozaki E, Matsuda M, Kuboki K, Ogura M, Ichimura T, Keisho C, Mizunuma N, Hatake K. [Relative dose intensity of FOLFOX4 regimen]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.11; 35 (11): 1895-900. ( PubMed )

庄司 大悟, 松阪 諭, 渡邊 知映, 末永 光邦, 篠崎 英司, 松田 正典, 久保木 恭利, 小倉 真理子, 市村 崇, 陳 勁松, 水沼 信之, 畠 清彦. FOLFOX4療法におけるRDI(Relative Dose Intensity)の検討 癌と化学療法. 2008.11; 35 (11): 1895-1900. ( 医中誌 )

渡邉 利泰, 水沼 信之, 末永 光邦, 畠 清彦. 【大腸癌の化学療法】大腸癌化学療法における副作用対策をどう行うか主な薬剤の特徴的な副作用とその対策　ベバシズマブ 消化器の臨床. 2008.10; 11 (5): 564-568. ( 医中誌 )

Kamisugi K, Matsusaka S, Imada H, Shoji D, Nakamoto E, Yokokawa T, Kawakami K, Hirata Y, Nawano K, Ogawa M, Shinozaki E, Suenaga M, Mizunuma N, Hatake K, Hama T. [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.08; 35 (8): 1331-5. ( PubMed )

神杉 香代子, 松阪 諭, 今田 洋司, 庄司 大悟, 中本 恵理, 横川 貴志, 川上 和宜, 平田 良美, 縄野 一美, 小川 恵, 篠崎 英司, 末永 光邦, 水沼 信之, 畠 清彦, 濱 敏弘. FOLFIRI療法の副作用調査に基づいた患者向け説明書の作成 癌と化学療法. 2008.08; 35 (8): 1331-1335. ( 医中誌 )

Kuboki Y, Ichimura T, Ogura M, Matsuda M, Suenaga M, Shinozaki E, Matsuzaka S, Chin K, Mizunuma N, Hatake K. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.05; 35 (5): 781-5. ( PubMed )

久保木 恭利, 市村 崇, 小倉 真理子, 松田 正典, 末永 光邦, 篠崎 英司, 松阪 諭, 陳 勁松, 水沼 信之, 畠 清彦. 高齢者進行・再発大腸癌症例に対するFOLFOX4療法の検討 癌と化学療法. 2008.05; 35 (5): 781-785. ( 医中誌 )

末永 光邦. 【大腸疾患の実地診療　増加する大腸癌と炎症性腸疾患への対応】大腸疾患の実地診療・トピックス　大腸癌　大腸癌の分子標的併用療法の有効性 Medical Practice. 2008.04; 25 (4): 661-662. ( 医中誌 )

末永 光邦. 【大腸癌治療UPDATE】サポート・医療環境　チーム・アバスチンと癌短期化学療法研修 医学のあゆみ. 2008.04; 225 (1): 67-73. ( 医中誌 )

Matsuda M, Matsusaka S, Kuboki Y, Itimura T, Ogura M, Suenaga M, Syouji D, Watanabe C, Chin K, Mizunuma N, Hatake K. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.03; 35 (3): 461-6. ( PubMed )

松田 正典, 松阪 諭, 久保木 恭利, 市村 崇, 小倉 真理子, 末永 光邦, 庄司 大吾, 渡邊 知映, 陳 勁松, 水沼 信之, 畠 清彦. 進行大腸癌に対するFOLFOX4療法による末梢神経障害の回復の解析 癌と化学療法. 2008.03; 35 (3): 461-466. ( 医中誌 )

Suenaga M, Nishina T, Hyodo I, Munakata M, Koizumi W, Mishima H, Sato A, Mizunuma N, Hatake K. [A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.02; 35 (2): 255-60. ( PubMed )

末永 光邦, 仁科 智裕, 兵頭 一之介, 棟方 正樹, 小泉 和三郎, 三嶋 秀行, 佐藤 温, 水沼 信之, 畠 清彦. 治癒切除不能の進行・再発結腸・直腸癌に対するOxaliplatin(L-OHP)+Infusional 5-FU/l-LV療法(FOLFOX4レジメン)の安全性確認試験 癌と化学療法. 2008.02; 35 (2): 255-260. ( 医中誌 )

Imada H, Kawakami K, Hiraoka T, Higuchi S, Takahashi G, Aoyama T, Shinozaki E, Suenaga M, Matsuzaka S, Hama T. [Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions]. Gan to kagaku ryoho. Cancer & chemotherapy. 2007.09; 34 (9): 1425-30. ( PubMed )

今田 洋司, 川上 和宜, 平岡 知子, 樋口 秀太郎, 高橋 郷, 青山 剛, 篠崎 英司, 末永 光邦, 松阪 諭, 濱 敏弘. FOLFOX 4療法の副作用集計データに基づく患者向け説明書の作成 癌と化学療法. 2007.09; 34 (9): 1425-1430. ( 医中誌 )

末永 光邦. 【がん外来化学療法コンセプトシート】新規導入薬剤　新規抗癌剤を導入するための準備　Avastin 医学のあゆみ. 2007.09; 222 (13): 1139-1143. ( 医中誌 )

末永 光邦. 【がん診療における重症感染と化学療法を含む総括的治療】消化器癌治療における感染症 化学療法の領域. 2006.04; 22 (5): 792-794. ( 医中誌 )

庄司 大悟, 水津 ちづる, 渡邊 知映, 水沼 信之, 陳 勁松, 高橋 俊二, 伊藤 良則, 徳留 なほみ, 末永 光邦, 宇良 敬, 畠 清彦. 固形がん化学療法施行患者における貧血発現状況に関する調査研究 血液・腫瘍科. 2006.02; 52 (2): 226-236.

末永 光邦, 大山 繁和, 佐藤 貴弘, 山本 順司, 山口 俊晴. 胃癌術後に抗血漿タンパク質抗体による非溶血性輸血副作用を呈した1例 臨床外科. 2004.10; 59 (10): 1361-1364. ( 医中誌 )

永野 秀樹, 大山 繁和, 末永 光邦, 佐藤 貴弘, 瀬戸 泰之, 山口 俊晴, 武藤 徹一郎, 山口 明夫. 食事制限とBMI変化からみた胃癌術後栄養指導評価 日本消化器外科学会雑誌. 2004.06; 37 (6): 648-655. ( 医中誌 )

永野 秀樹, 大山 繁和, 大平 寛典, 末永 光邦, 細井 則人, 佐藤 貴弘, 太田 惠一朗, 太田 博俊, 山口 俊晴, 武藤 徹一郎. 患者からみた噴門側胃切除術後のQOL評価 日本外科学会雑誌. 2003.04; 104 (臨増): 621. ( 医中誌 )

太田 惠一朗, 末永 光邦, 佐藤 貴弘, 阪本 良弘, 大山 繁和, 上野 雅資, 関 誠, 山本 順司, 大矢 雅敏, 畦倉 薫, 太田 博俊, 山口 俊晴. 【胃全摘後の再建法】十二指腸への再建ルートのpros and cons　胃全摘後の再建方法;空腸間置法とdouble tract法 消化器外科. 2003.02; 26 (2): 203-211. ( 医中誌 )

佐藤 貴弘, 山口 俊晴, 太田 惠一朗, 大山 繁和, 上野 雅資, 永野 秀樹, 大平 寛典, 細井 則人, 末永 光邦, 武藤 徹一郎. Stage IV胃癌穿孔症例に対し好中球エラスターゼ阻害薬を投与し,救命し得た1例 Progress in Medicine. 2003.01; 23 (1): 457-458. ( 医中誌 )

末永 光邦, 徳重 正弘, 久保 文武, 福留 哲朗, 肝付 兼達, 愛甲 孝. 慢性膵炎に対する十二指腸温存膵頭切除術・膵空腸側々吻合術後11年目に発症した肝膿瘍破裂の1例 日本消化器外科学会雑誌. 2001.03; 34 (3): 224-228. ( 医中誌 )

末永 光邦, 松本 英彦, 坂元 史典, 小川 洋樹, 豊山 博信, 柳 正和, 西島 浩雄, 下高原 哲朗, 愛甲 孝. 特異な形態を呈した後縦隔気管支原性嚢腫の1例 日本呼吸器外科学会雑誌. 1999.11; 13 (7): 862-867. ( 医中誌 )

末永　光邦、畠　清彦　他. 腫瘍内科ゴールデンハンドブック. 南江堂, 2010.07 I-2 アレルギー、V-2 外科療法の概略と適応、VI-4 アレルギー、VI-6 bevacizumab,付録　NCCNガイドライン

末永　光邦、畠　清彦　他. がん診療レジデントハンドブック. 中外医学社, 2009.12 2-12効果判定、RECIST, 5-3高血圧の管理、6-2外科医へのコンサルトはどうあるべきか？ 6-17チームアバスチン (ISBN : 9784498022423)

末永　光邦、畠　清彦　他. 癌薬物療法専門医. 腫瘍内科オリエンテーション. 医薬ジャーナル社, 2008.12 癌薬物療法専門医 (ISBN : 9784753223404)

末永　光邦　他. Cancer Treatment Navigator. メディカルレビュー社, 2008.11 抗体を含む抗癌剤のアレルギー (ISBN : 9784779203220)

末永　光邦、畠　清彦　他. がんの外来化学療法のマネジメント. 医薬ジャーナル社, 2008.02 チームアバスチンの形成と新規薬剤の導入、アレルギーとinfusion reaction (ISBN : 9784753222827)

末永光邦、小西文雄　他. よくわかる大腸癌のすべて. 永井書店, 2007.04 進行-再発大腸癌に対する化学療法、ミニコラム”肝動注の位置づけ (ISBN : 978-4-8159-1786-9)

末永　光邦、畠　清彦　他. がん薬物療法専門医になるには？なったら？. 真興交易（株）医書出版部, 2007.04 消化器領域からがん薬物療法専門医を目指して (ISBN : 978-4-88003-795-0)

Ryo Morikawa, Kentaro, Shuntaro Yasuda, Rika Noji, Satoru Aoyama, Yoshihito Kano, Shingo Sato, Sadakatsu Ikeda, Masashi Nagata, Takehiko Mori, Mitsukuni Suenaga. Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors. 20th the Japanese Society of Medical Oncology Annual Meeting 2023.03.16 Fukuoka

Mitsukuni Suenaga, Shinichi Yamauchi, Yuya Sato, Rika Noji, Ryo Morikawa, Yoshihito Kano, Masanori Tokunaga, Yusuke Kinugasa. Impact of chemotherapy on COVID-19 vaccination in patients with gastrointestinal cancer.. 2023 ASCO GI Cancers Symposium 2023.01.21 SF, US

Takeshi Yamada, Nobuhisa Matsuhashi, Takao Takahashi, Keiji Hirata, Takeshi Nagasaka, Yuki Nakamura, Kazuhiro Sakamoto, Keiji Koda, Kazuhiro Hiramatsu, Hiroshi Matsuoka, Hidekazu Kuramochi, Hideyuki Ishida, Kozo Kataoka, Hajime Yokomizo, Yoshinori Kagawa, Mitsukuni Suenaga, Ryo Ohta, Akihisa Matsuda, Hiroshi Yoshida. Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.. 2023 ASCO GI Cancers Symposium 2023.01.21 SF, US

Ryo Morikawa, Kentaro Nitta, Shuntaro Yasuda, Rika Noji, Yoshihito Kano, Shingo Sato, Sadakatsu Ikeda, Masashi Nagata, Takehiko Mori, Mitsukuni Suenaga. Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors.. 2023 ASCO GI Cancers Symposium 2023.01.19 SF, US

Mitsukuni Suenaga, Shinichi Yamauchi, Taiki Masuda, Marie Hanaoka, Noriko Iwata, Yuya Sato, Yuya Sato, Chiharu Tomii, Masanori Tokunaga, Yusuke Kinugasa. COVID-19 vaccination in gastrointestinal cancer patients during chemotherapy at a single institute experience. 2022 the Japanese Society Of Medical Oncology Annual Meeting 2022.02.17 Kyoto

末永光邦、馬島哲夫、若槻尊、清宮啓之. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. 第18 回日本臨床腫瘍学会学術集 2021.02.18 Virtual Congress

上今別府 大作, 若槻 尊, 高張 大亮, 福田 直樹, 佐藤 太龍, 鈴木 健, 大隅 寛木, 中山 厳馬, 末永 光邦, 大木 暁, 小倉 真理子, 篠崎 英司, 山口 研成. 当院でのAFP産生切除不能進行・再発胃癌に対するラムシルマブ併用化学療法の検討(Treatment efficacy of ramucirumab-based chemotherapy in patients with AFP producing gastric cancer). 日本胃癌学会総会記事 2020.03.01

Matsusaka Satoshi, Hanna Diana L., Ning Yan, Yang Dongyun, Cao Shu, Berger Martin D., Miyamoto Yuji, Suenaga Mitsukuni, Dan Shingo, Mashima Tetsuo, Seimiya Hiroyuki, Zhang Wu, Lenz Heinz-Josef. 上皮成長因子受容体のmRNA発現　レゴラフェニブから逃れるための分子機序である可能性(Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib). Cancer Science 2020.02.01

Martin D. Berger, Inti Zlobec, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Alessandro Lugli, Heinz-Josef Lenz. Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer. ASCO-GI 2020.01

Suenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Seimiya, H., Yamaguchi, K.. IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2020.01

Suenaga, M., Zhang, W., Mashima, T., Schirripa, M., Cao, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Barzi, A., Lenz, H. J.. Gene polymorphisms of CCL3, CCL4, CCL5, and CCR5 network in metastatic colorectal cancer patients treated with regorafenib. ASCO Gastrointestinal Cancers Symposium 2020.01

Daisaku Kamiimabeppu, Takeru Wakatsuki, Daisuke Takahari, Naoki Fukuda, Hiroki Osumi, Izuma Nakayama, Mariko Ogura, Tarou Sato, Akira Ooki, Eiji Shinozaki, Mitsukuni Suenaga, Keisho Chin, Kensei Yamaguchi. Treatment efficacy of ramucirumab-based chemotherapy in patients with alpha-fetoprotein producing gastric cancer (AFPGC).. ASCO-GI 2020.01

Martin D. Berger, Shu Cao, Inti Zlobec, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Alessandro Lugli, Heinz-Josef Lenz. Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.. ASCO annual meeting 2019.06

Fukuda Naoki, Takahari Daisuke, Suzuki Takeshi, Ota Yumiko, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Yamaguchi Kensei. Ramucirumab+weekly nab-Paclitaxel併用療法で治療された胃癌患者の成績(Real world outcomes of gastric cancer patients treated with ramucirumab plus weekly nab-pactitaxel). 日本胃癌学会総会記事 2019.02.01

Ota Yumiko, Takahari Daisuke, Fukuda Naoki, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisyo, Yamaguchi Kensei. 進行胃癌に対するnivolumabの効果および予後因子(Outcome and prognostic factors of Nivotumab for advanced gastric cancer in our institution). 日本胃癌学会総会記事 2019.02.01

Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz. Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE. ASCO Gastrointestinal Cancers Symposium 2019.01

Suenaga, M., Cao, S., Zhang, W., Matsusaka, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Schirripa, M., Barzi, A., Ueno, M., Lenz, H. J. . Role of enterocyte-specific gene polymorphisms in adjuvant treatment for stage III colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2019.01

Yukiko Izawa, Takashi Ichimura, Keisho Chin, Eiji Shinozaki, Daisuke Takahari, Mitsukuni Suenaga, Mariko Ogura, Takeru Wakatsuki, Hiroki Osumi, Izuma Nakayama, Shinji Mine, Naoki Hiki, Naoki Ishizuka, Kensei Yamaguchi. Feasibility study of diet counseling (DC) with oral nutritional supplements (ONS) for advanced esophageal and gastric cancer during chemotherapy (CT) or chemoradiotherapy (CRT): First report of ONS compliance from a prospective randomized controlled clinical study (DiCON study).. ASCO-GI 2019.01

Kitagawa Y, Osumi H, Shinozaki E, Ota Y, Nakayama I, Suzuki T, Wakatsuki T, Ichimura T, Ogura M, Ooki A, Takahari D, Suenaga M, Chin K, Yamaguchi K.. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.. ASCO-GI 2019.01

M Suenaga, T Wakatsuki, M Ogura, T Ichimura, E Shinozaki, I Nakayama, H Osumi, Y Ota, K Chin, T Mashima, H Seimiya, D Takahari, K Yamaguchi.. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.. ESMO congress 2018.10

M. Berger, S. Stintzing, V. Heinemann, S. Cao, D. Yang, Y. Miyamoto, M. Suenaga, D.L. Hanna, S. Soni, A. Puccini, R. Tokunaga, M. Naseem, F. Battaglin, M. McSkane, W. Zhang, H.-J. Lenz. Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3. ESMO congress 2018.10

H. Osumi, E. Shinozaki, H. Zembutsu, Y. Takeda, T. Wakatsuki, T. Ichimura, Y. Ota, I. Nakayama, M. Ogura, M. Suenaga, D. Takahari, K. Chin, A. Saiura, S. Takahashi, T. Noda, K. Yamaguch. Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis. ESMO congress 2018.10

R. Takahashi, T. Wakatsuki, N. Yamamoto, S. Taguchi, E. Shinozaki, H. Osumi, M. Ogura, T. Ichimura, D. Takahari, M. Suenaga, K. Chin, M. Oguchi, M. Ueno, K. Yamaguchi. p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan. ESMO congress 2018.10

Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kensei. 既治療のKRASエクソン2野生型大腸癌に対するサードライン療法としてのセツキシマブとイリノテカンの隔週治療の第II相試験(Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer). Cancer Science 2018.08.01

Suenaga, M., Schirripa, M., Loupakis, F., Cao, S., Zhang, W., Cremolini, C., Lonardi, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Soni, S., Barzi, A., Yamaguchi, T., Falcone, A., Lenz, H. J.. Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. 54th ASCO annual meeting 2018.06

福田 直樹, 高張 大亮, 太田 弓子, 大隅 寛木, 中山 厳馬, 若槻 尊, 市村 崇, 小倉 真理子, 末永 光邦, 篠崎 英司, 陳 勁松, 山口 研成. 胃癌・肝転移のラムシルマブによる画像上形態学的変化の頻度・臨床的意義に関する検討(Morphologic change in gastric cancer patients with liver metastasis treated with ramucirumab). 日本胃癌学会総会記事 2018.03.01

Suenaga, M., Mashima, T., Kawata, N., Dan, S., Wakatsuki, T., Shinozaki, E., Ichimura, T., Ogura, M., takahari, D., Osumi, H., Ota, Y., Chin, K., Seimiya, H., Yamaguchi, K., Yamaguchi, T.. Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation.. ASCO Gastrointestinal Cancers Symposium 2018.01

Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Ning, Y., Bergamo, F., Zagonel, V., Rossini, D., Borelli, B., Okazaki, S., Berger, M., Miyamoto, Y., Gopez, R., Barzi, A., Yamaguchi, T., Loupakis, F., Lenz, H. J.. Matrix metalloproteinase-related gene polymorphisms predict efficacy of regorafenib in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2018.01

Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Cremolini, C., Murgioni, S., Lonardi, S., Ning, Y., Okazaki, S., Berger, M. D., Miyamoto, Y., Gopez, R., Barzi, A., Loupakis, F., Falcone, A., Lenz, H.. Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. ASCO Gastrointestinal Cancers Symposium 2018.01

Yuta Ushida, Eiji Shinozaki, Keisho Chin, Mitsukuni Suenaga, Daisuke Takahari, Masato Ozaka, Mariko Ogura, Takashi Ichimura, Takeru Wakatsuki, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Yumiko Ota, Kensei Yamaguchi. Clinical outcomes of anti-EGFR antibody treatment for right-sided colon cancer patients without RAS, BRAF, and PIK3CA mutations in the later line.. ASCO-GI 2018.01

Daisuke Takahari, Takeru Wakatsuki, Tetsuo Mashima, Keisho Chin, Takashi Ichimura, Mariko Ogura, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Izuma Nakayama, Yumiko Ota, Eiji Shinozaki, Mitsukuni Suenaga, Naomi Kawata, Yuki Horiike, Hiroyuki Seimiya, Naoya Fujita, Kensei Yamaguchi. Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer.. ASCO-GI 2018.01

Yumiko Ota, Takeru Wakatsuki, Tetsuo Mashima, Daisuke Takahari, Keisho Chin, Takashi Ichimura, Mariko Ogura, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Izuma Nakayama, Eiji Shinozaki, Mitsukuni Suenaga, Naomi Kawata, Yuki Horiike, Hiroyuki Seimiya, Naoya Fujita, Kensei Yamaguchi. Plasma biomarker dynamics following ramucirumab treatment and survival analysis after ramucirumab treatment failure in patients with advanced gastric cancer.. ASCO-GI 2018.01

Ryo Takahashi, Takeru Wakatsuki, Eiji Shinozaki, Senzo Taguchi, Yoshiya Fujimoto, Hiroki Osumi, Yumiko Ota, TOMOHIRO MATSUSHIMA, Mariko Ogura, Takashi Ichimura, Daisuke Takahari, Mitsukuni Suenaga, Keisho Chin, Masahiko Oguchi, Masashi Ueno, Kensei Yamaguchi. Chemoradiation for the treatment of locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan.. ASCO-GI 2018.01

Tomoyo Oguri, Daisuke Takahari, Yumiko Ota, Hiroki Osumi, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Takashi Ichimura, Mitsukuni Suenaga, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi. The clinical analysis of thromboembolism in esophagogastric cancer in Japan: A single institute experience.. ASCO-GI 2018.01

Shusuke Yagi, Eiji Shinozaki, Keisho Chin, Mitsukuni Suenaga, Daisuke Takahari, Mariko Ogura, Takashi Ichimura, Takeru Wakatsuki, Masato Ozaka, Izuma Nakayama, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Kensei Yamaguch. Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer.. ASCO-GI 2018.01

Tomoyuki Nagaoka, Eiji Shinozaki, Ryosuke Watanabe, Eiko Ueno, Yumiko Ota, Hiroki Osumi, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Mitsukuni Suenaga, Takashi Ichimura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi. Clinical significance of morphologic response and tumor shrinkage as predictive factors of Capeox+bevacizumab in 1st line treatment of metastatic colorectal cancer.. ASCO-GI 2018.01

Nakayama Izuma, Chin Keisho, Matsushima Tomohiro, Takahari Daisuke, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Wakatsuki Takeru, Ichimura Takashi, Osumi Hiroki, Yamaguchi Kensei. 腹腔細胞診陽性で肉眼的所見では腹膜転移を認めない進行性胃癌患者の治療に対するS-1+シスプラチンとS-1単剤療法の後向きによる比較検討(Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis). International Journal of Clinical Oncology 2017.12.01

小口 正彦, 室伏 景子, 田口 千藏, 吉岡 靖生, 角 美奈子, 上野 雅資, 福長 洋介, 長山 聡, 秋吉 高志, 小西 毅, 藤本 佳也, 山口 研成, 篠崎 英司, 末永 光邦, 松阪 諭. 「それぞれの癌」診断・治療の現状と展望　直腸癌　局所進行直腸癌に対する化学放射線療法. 日本癌治療学会学術集会抄録集 2017.10.01

Suenaga, M., Cao, S., Stintzing, S., Zhang, W., Yang, D., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Schirripa, M., Gopez, R., Melendez, E., Soni, S., Barzi, A., Yamaguchi, T., Heinemann, V., Lenz, H.. Genetic polymorphisms of CCL5 and CCR5 to predict efficacy of cetuximab-based treatment in metastatic colorectal cancer patients depending on primary tumor location.. 53rd ASCO annual meeting 2017.06

Yuji Miyamoto, Sebastian Stintzing, Volker Heinemann, Wu Zhang, Shu Cao, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Shivani Soni, Satoshi Matsusaka, Yan Ning, Dongyun Yang, Roel Gopez, Elizabeth Melendez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, and Heinz-Josef Lenz. Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy. ASCO annual meeting 2017.06

Yuji Miyamoto, Fotios Loupakis, Wu Zhang, Shu Cao, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Shivani Soni, Satoshi Matsusaka, Yan Ning, Dongyun Yang, Roel Gopez, Elizabeth Melendez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, Alfredo Falcone, and Heinz-Josef Lenz. Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy. ASCO Annual Meeting 2017.06

Martin D. Berger, Sebastian Stintzing, Dongyun Yang, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Shivani Soni, Roel Gopez, Elizabeth Melendez, Wu Zhang, Volker Heinemann, and Heinz-Josef Lenz. Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Annual Meeting 2017.06

Suenaga, M., Cao, S., Zhang, W., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Schirripa, M., Gopez, R., Melendez, E., Soni, S., Barzi, A., Yamaguchi, T., Lenz, H. . Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.. 53rd ASCO annual meeting 2017.06

Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Marmorino, F., Bergamo, F., Antoniotti, C., Rossini, D., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Gopez, R., Hanna, D., Barzi, A., Mashima, T., Yamaguchi, T., Loupakis, F., Lenz , H.. Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2017.01

Martin D. Berger, Sebastian Stintzing, Dongyun Yang, Mitsukuni Suenaga, Yuji Miyamoto, Shu Cao, Shivani Soni, Roel Gopez, Diana L. Hanna, Wu Zhang, Volker Heinemann, Heinz-Josef Lenz. Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Gastrointestinal Cancers Symposium 2017.01

Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Shu Cao, Yan Ning, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Roel Gopez, Diana L. Hanna, Wu Zhang, Heinz-Josef Lenz. Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Gastrointestinal Cancers Symposium 2017.01

Yuji Miyamoto, Sebastian Stintzing, Wu Zhang, Shu Cao, Yan Ning, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Shivani Soni, Satoshi Matsusaka, Dongyun Yang, Roel Gopez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, Volker Heinemann, Heinz-Josef Lenz. Polymorphisms in adipokine-related genes to predict treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy.. ASCO Gastrointestinal Cancers Symposium 2017.01

Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Salvatore, L., Lonardi, S., Moretto, R., Borelli, B., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Gopez, R., Hanna, D., Barz, A., Wakatsuki, T., Yamaguchi, T., Loupakis, F., Lenz, H.. Lenz, H. Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference.. ASCO Gastrointestinal Cancers Symposium 2017.01

S. Okazaki, F. Loupakis, M. Schirripa, S. Cao, W. Zhang, D. Yang, Y. Ning, M. Berger, Y. Miyamoto, M. Suenaga, R. Gopez, B.B. Borelli, C. Cremolini, A. Falcone, S. Lonardi, L.Salvatore, H. Uetake, T. Kawano, T. Helentjaris, H.-J. Lenz. Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. ESMO congress 2016.10

Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Berger, M., West, J., Cremolin, C., Lonardi, S., Battaglin, F., Ning, Y., Horiike, Y., Yamamoto, N., Okazaki, S., Miyamoto, Y., Hanna, D., Barzi, A., Loupakis, F., Falcone, A., Lenz, H.. Genetic variants of Pin1 to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).. ASCO Annual Meeting. 2016.06

Roel Gopez, Marta Schirripa, Wu Zhang, Shu Cao, Satoshi Okazaki, Dongyun Yang, Fotios Loupakis, Martin D. Berger, Yan Ning, Yuji Miyamoto, Mitsukuni Suenaga, Jordan David West, Diana L. Hanna, Afsaneh Barzi, Alfredo Falcone, Sebastian Stintzing, Volker Heinemann, Heinz-Josef Lenz. IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial.. ASCO Annual Meeting 2016.06

Marta Schirripa, Wu Zhang, Dongyun Yang, Shu Cao, Satoshi Okazaki, Fotios Loupakis, Martin D. Berger, Yan Ning, Afsaneh Barzi, Yuji Miyamoto, Mitsukuni Suenaga, Roel Gopez, Jordan David West, Diana L. Hanna, Sara Lonardi, Francesca Bergamo, Chiara Cremolini, Alfredo Falcone, Heinz-Josef Lenz. NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial. ASCO Annual Meeting 2016.06

Martin D. Berger ,Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Yu Sunakawa, Yan Ning, Satoshi Matsusaka, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Jordan David West, Diana L. Hanna, Afsaneh Barzi, Wu Zhang, Heinz-Josef Lenz. MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Annual Meeting 2016.06

Satoshi Matsusaka, Yan Ning, Dongyun Yang, Wu Zhang, Diana L. Hanna, Shu Cao, Mitsukuni Suenaga, Satoshi Okazaki, Martin D. Berger, Heinz-Josef Lenz. Epidermal growth factor receptor mRNA expression in circulating tumor cells as a potential mechanism of molecular escape from regorafenib therapy. 2016.06

Shu Cao, Dongyun Yang, Sebastian Stintzing, Fotios Loupakis, Wu Zhang, Yan Ning, Marta Schirripa, Mitsukuni Suenaga, Satoshi Okazaki, Yuji Miyamoto, Afsaneh Barzi, Heinz-Josef Lenz. Identifying predictive SNPs in patients with metastatic colorectal cancer (mCRC) using Random Survival Forests. ASCO Annual Meeting 2016.06

Jordan David West, Wu Zhang, Sebastian Stintzing, Yu Sunakawa, Dongyun Yang, Shu Cao, Yan Ning, Martin D. Berger, Roel Gopez, Yuji Miyamoto, Satoshi Okazaki, Mitsukuni Suenaga, Marta Schirripa, Afsaneh Barzi, Diana L. Hanna, Akihito Tsuji, Wataru Ichikawa, Volker Heinemann, Heinz-Josef Lenz. Genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3) or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR). ASCO Annual Meeting 2016.06

Yuji Miyamoto, Sebastian Stintzing, Fotios Loupakis, Wu Zhang, Shu Cao, Yan Ning, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Satoshi Matsusaka, Dongyun Yang, Jordan David West, Roel Gopez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, Volker Heinemann, Heinz-Josef Lenz. Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE. ASCO Annual Meeting 2016.06

Satoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Martin D. Berger, Jordan David West, Roel Gopez, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Afsaneh Barzi, Diana L. Hanna, Akihito Tsuji, Wataru Ichikawa, Volker Heinemann, William DePaolo, Heinz-Josef Lenz. Polymorphisms in toll-like receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in patients with metastatic colorectal cancer (mCRC). ASCO Annual Meeting 2016.06

Yan Ning, Sebastian Stintzing, Wu Zhang, Dongyun Yang, Diana L. Hanna, Satoshi Okazaki, Martin D. Berger, Yuji Miyamoto, Jordan David West, Mitsukuni Suenaga, Marta Schirripa, Afsaneh Barzi, Volker Heinemann, Heinz-Josef Lenz. Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort. ASCO Annual Meeting 2016.06

Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Yu Sunakawa, Yan Ning, Satoshi Matsusaka, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Jordan David West, Afsaneh Barzi, Diana L. Hanna, Wu Zhang, Heinz-Josef Lenz. Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Annual Meeting 2016.06

Wu Zhang, Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Dongyun Yang, Martin D. Berger, Jordan David West, Yan Ning, Takeru Wakatsuki, Tetsuo Mashima, Satoshi Okazaki, Yuji Miyamoto, Diana L. Hanna, Federica Marmorino, Lisa Salvatore, Roberto Moretto, Beatrice Borelli, Afsaneh Barzi, Fotios Loupakis, Heinz-Josef Lenz. Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. ASCO Annual Meeting 2016.06

Marta Schirripa, Dongyun Yang, Fotios Loupakis, Carlotta Antoniotti, Chiara Cremolini, Shu Cao, Satoshi Okazaki, Martin D. Berger, Yan Ning, Yuji Miyamoto, Mitsukuni Suenaga, Roberto Moretto, Francesca Bergamo, Francesca Battaglin, Sara Lonardi, Roel Gopez, Jordan David West, Wu Zhang, Alfredo Falcone, Heinz-Josef Lenz. Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients. ASCO Annual Meeting 2016.06

Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Berger, M., West, J., Ning, Y., Salvatore, L., Rossini, D., Antoniotti, C., Inoue, R., Matsusaka, S., Okazaki, S., Miyamoto, Y., Hanna, D., Barzi, A., Loupakis, F., Lenz, H.. Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. ASCO annual meeting 2016.06

Osumi Hiroki, Yoshio Toshiyuki, Chin Keisho, Ogura Mariko, Kumekawa Yosuke, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Miyamoto Yuji, Morishige Kenjiro, Ishiyama Akiyoshi, Hirasawa Toshiaki, Tsuchida Tomohiro, Yamamoto Yorimasa, Fujisaki Junko, Igarashi Masahiro, Mizunuma Nobuyuki. 化学療法は同時性重複食道癌患者における胃癌第1期に有効である(Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer). Gastric Cancer 2016.04.01

陳 勁松, 小倉 真理子, 市村 崇, 高張 大亮, 篠崎 英司, 尾阪 将人, 松阪 諭, 末永 光邦, 水沼 信之. 高齢者胃癌の治療戦略　80歳以上の転移進行胃癌患者への化学療法は有用か?(Systemic chemotherapy for 80 years or over patients with advanced gastric cancer). 日本胃癌学会総会記事 2016.03.01

Satoshi Okazaki, Sebastian Stintzing, Volker Heinemann, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Satoshi Matsusaka, Martin D. Berger, Jordan D. West, Yuji Miyamoto, Mitsukuni Suenaga, Heinz-Josef Lenz. Association of TLR9 polymorphism with overall survival in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab enrolled in FIRE3.. ASCO-GI 2016.01

Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Yu Sunakawa, Yan Ning, Satoshi Matsusaka, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Jordan David West, Wu Zhang, Nicos Petasis, Heinz-Josef Lenz. Serum amyloid α (SAA-1) SNP rs12218 to predict outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial.. ASCO-GI 2016.01 SF, US

Tsuyoshi Konishi, Eiji Shinozaki, Keiko Murofushi, Masashi Ueno, Yosuke Fukunaga, Satoshi Nagayama, Yoshiya Fujimoto, Takashi Akiyoshi, Mitsukuni Suenaga, Satoshi Matsusaka, Akiko Chino, Hiroshi Kawachi, Noriko Yamamoto, Yuichi Ishikawa, Masahiro Igarashi, Masahiko Oguchi, Nobuyuki Mizunuma, Takeshi Sano, Toshiharu Yamaguchi. Phase II trial of induction mFOLFOX6 plus bevacizumab followed by neoadjuvant S-1-based chemoradiation for MRI-defined poor-risk rectal cancer.. ASCO-GI 2016.01

M. Suenaga, N. Mizunuma, S. Matsusaka, E. Shinozaki, M. Ozaka, M. Ogura, K. Chin, T. Yamaguchi.. A phase II study of Oxaliplatin Reintroduction in patients pretreated with Oxaliplatin and Irinotecan for Advanced Colorectal Cancer (RE-OPEN study).. ASCO Gastrointestinal Cancers Symposium 2015.01

Mitsukuni Suenaga, Nobuyuki Mizunuma, Satoshi Matsusaka, Eiji Shinozaki, Masato Ozaka, Mariko Ogura, Keisho Chin, Toshiharu Yamaguchi. A Phase I/II study of Bi-weekly XELIRI with capecitabine 1,000 mg/m2 twice daily and irinotecan 180 mg/m2 plus bevacizumab (BV) for patient with Metastatic Colorectal Cancer as second-line chemotherapy . ESMO annual congress 2014.09.29 Madrid

Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Mariko Ogura, Masato Ozaka, Izuma Nakayama, Takeru Wakatsuki, Keisho Chin, Nobuyuki Mizunuma, Toshiharu Yamaguchi.. SDF-1 and VEGF-C is potential circulating angiogenic biomarkers for bevacizumab in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2014.01

Hiroki Osumi, Satoshi Matsusaka, Mitsukuni Suenaga, Takeru Wakatsuki, Mariko Ogura, Masato Ozaka, Eiji Shinozaki, Keisho Chin, Nobuyuki Mizunuma. Quantitative analysis of the impact of deepness of response on survival time following patients with metastatic colorectal cancer treated by chemotherapy and anti-EGFR monoclonal antibodies.. ASCO-GI 2014.01 SF, US

Takeru Wakatsuki, Keisho Chin, Satoshi Matsusaka, Mariko Ogura, Masato Ozaka, Mitsukuni Suenaga, Eiji Shinozaki, Izuma Nakayama, Nobuyuki Mizunuma. Exploratory analysis to investigate clinical factors that may influence trastsuzumab efficacy in patients with HER2-positive gastric cancer.. ASCO-GI 2014.01 SF, US

Mitsukuni Suenaga, Nobuyuki Mizunuma, Satoshi Matsusaka, Eiji Shinozaki, Masato Ozaka, Mariko Ogura, Keisho Chin, Toshiharu Yamaguchi.. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study): Reports of interim analysis.. ASCO Gastrointestinal Cancers Symposium 2013.01

Itatani Yoshiro, Akiyoshi Takashi, Kuroyanagi Hiroya, Yamakawa Keiko, Noaki Rota, Konishi Tsuyoshi, Fujimoto Yoshiya, Ueno Masashi, Oya Masatoshi, Suenaga Mitsukuni, Yamaguchi Toshiharu. 病初は切除不能であった、骨盤壁に浸潤する局所進行直腸癌に対するFOLFOX4+bevacizumabと術前化学放射線療法施行後の全直腸間膜切除術　症例報告(Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case). Surgery Today 2012.01.01

Mitsukuni Suenaga, Satoshi Matsusaka, Nobuyuki Mizunuma, Eiji Shinozaki, Mariko Ogura, Masato Ozaka, Koichi Takagi, Toshiharu Yamaguchi, Kiyohiko Hatake.. Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2012.01

Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Nobuyuki Mizunuma, Kiyohiko Hatake, Toshiharu Yamaguchi.. A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part.. ASCO Gastrointestinal Cancers Symposium 2012.01

Yoshihito Ohhara, Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Kiyohiko Hatake. Comparison between the three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer.. ASCO-GI 2012.01 SF, US

Yoshihito Ohhara, Keisho Chin, Mariko Ogura, Mitsukuni Suenaga, Eiji Shinozaki, Satoshi Matsusaka, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Kiyohiko Hatake. What are the limiting factors related to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer?. ASCO-GI 2012.01 SF, US

Kazuyoshi Kawakami, Mitsukuni Suenaga, Takashi Yokokawa, Kazuo Sugita, Yutaro Mae, Eri Nakamoto, Hiroshi Imada, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Toshihiro Hama. Effect of moisturizers on prevention of hand-foot syndrome associated with capecitabine plus oxaliplatin.. ASCO-GI 2012.01 SF, US

Eiji Shinozaki, Noriko Yamamoto, Keisho Chin, Mariko Ogura, Mitsukuni Suenaga, Satoshi Matsusaka, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Kiyohiko Hatake. How many biopsy fragments will be necessary to assess HER2 status for gastric cancer?. ASCO-GI 2012.01 SF, US

Toshiyasu Watanabe, Eiji Shinozaki, Sho Kijima, Yoshihito Ohhara, Yasutoshi Kuboki, Koichi Takagi, Masato Ozaka, Mariko Ogura, Yoshinori Kikuchi, Mitsukuni Suenaga, Keisho Chin, Satoshi Matsusaka, Junichi Koike, Kimihiko Funahashi, Yoshihisa Urita, Nobuyuki Mizunuma, Kiyohiko Hatake, Hironori Kaneko, Motonobu Sugimoto. Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?. ASCO-GI 2012.01

Satoshi Matsusaka, Mitsukuni Suenaga, Yuji Mishima, Yasuhito Terui, Eiji Shinozaki, Nobuyuki Mizunuma, Kiyohiko Hatake. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.. ASCO-GI 2012.01

Dai Inoue, Satoshi Matsusaka, Noriko Yamamoto, Mitsukuni Suenaga, Yuji Mishima, Eiji Shinozaki, Yasuhito Terui, Nobuyuki Mizunuma, Yuichi Ishikawa, Kiyohiko Hatake. CD133 status influences in prognosis of patients with metastatic colorectal cancer receiving cetuximab.. ASCO-GI 2012.01 SF, US

Yoshitaka HONMA, Masataka TAGURI , Narikazu BOKU, Takahiro TSUSHIMA, Hideaki TAKAHASHI, Shinya UEDA, Tomohiro NISHINA, Hiroki KAWAI, Shunsuke KATO, Mitsukuni SUENAGA. Prognostic Factors of 127 Patients with Advanced Small-bowel Adenocarcinoma Treated with Systemic Chemotherapy. . ECCO annual meeting 2011.09

akahashi Hideaki, Taguri Masataka, Boku Narikazu, Tsushima Takahiro, Honma Yoshitaka, Ueda Shinya, Nishina Tomohiro, Kawai Hiroki, Kato Shunsuke, Kunieda Kenji, Suenaga Mitsukuni, Tamura Fumio, Uchino Keita, Hata Yasuhiro, Horimatsu Takahiro. Prognostic factors of 127 patients with advanced small-bowel adenocarcinoma treated with systemic chemotherapy. 第9回日本臨床腫瘍学会学術集会 2011.07.22 横浜

大場 大, 陳 勁松, 篠崎 英司, 末永 光邦, 松阪 諭, 水沼 信之, 畠 清彦, 山口 俊晴. Second-line settingでのCPT-11の利用は進行性胃癌の生存率を向上させる(Availability of CPT-11 in second-line setting provides survival benefit for advanced gastric cancer). 日本消化器外科学会総会 2011.07.01

Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Kuniyoshi Ryoko, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. 転移性結腸直腸癌の日本人患者における化学療法に対する反応性を決定するためのサロゲートマーカーとしての循環中腫瘍細胞(Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer). Cancer Science 2011.06.01

S. Matsusaka, N. Mizunuma, M. Suenaga, K. Chin, E. Shinozaki, T. Watanabe, Y. Kawazoe, Y. Kuboki, Y. Terui, K. Hatake. Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2011.01.22 SF, US

T. Tsushima, N. Boku, Y. Honma, H. Takahashi, S. Ueda, T. Nishina, H. Kawai, S. Kato, M. Suenaga, F. Tamura. Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma.. ASCO Gastrointestinal Cancers Symposium 2011.01.21 SF, US

S. Matsusaka, K. Chin, N. Mizunuma, M. Ogura, M. Suenaga, M. Ozaka, K. Takagi, M. Oba, Y. Mishima, K. Hatake. Use of circulating tumor cells to predict response to chemotherapy in patients with advanced gastric cancer.. ASCO Gastrointestinal Cancers Symposium 2011.01.20 SF, US

M. Suenaga, S. Matsusaka, T. Watanabe, K. Takagi, Y. Kuboki, M. Ozaka, E. Shinozaki, K. Chin, N. Mizunuma, K. Hatake.. Coagulo-fibrinolytic activity as predictor of efficacy in bevacizumab-combined chemotherapy in metastatic colorectal cancer patients.. ASCO Gastrointestinal Cancers Symposium 2011.01

M. Suenaga, N. Mizunuma, S. Matsusaka, E. Shinozaki, M. Ogura, Y. Kuboki, T. Watanabe, M. Ozaka, K. Chin, K. Hatake.. Addition of bevacizumab to first-line FOLFOX improves efficacy, including response rate, progression-free survival and overall survival, in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2011.01

M. Suenaga, H. Imada, E. Nakamoto, S. Matsusaka, T. Watanabe, Y. Kawazoe, E. Shinozaki, K. Chin, N. Mizunuma, K. Hatake.. Optimal use of antihypertensive agents in management of bevacizumab-associated hypertension. . ASCO Gastrointestinal Cancers Symposium 2011.01

大場 大, 陳 勁松, 小倉 真理子, 久保木 恭利, 河添 悦昌, 渡邊 利泰, 高木 浩一, 尾阪 将人, 篠崎 英司, 末永 光邦, 松阪 諭, 水沼 信之, 畠 清彦. 進行胃癌におけるセカンドライン化学療法としてのイリノテカン　臨床における効果と実用性に関する後向き研究(Irinotecan as 2nd-line chemotherapy in advanced gastric cancer: Retrospective study of efficacy and feasibility in clinical practice). 日本消化器病学会雑誌 2010.09.01

Suenaga Mitsukuni, Ito Yoshinori, Hatake Kiyohiko, Takahashi Shunji, Yokoyama Masahiro, Hashigami Kiyoshi, Onozawa Yusuke, Yamazaki Kentaro, Hironaka Shuichi, Boku Narikazu. 分子標的治療　日本人の進行性固形腫瘍患者におけるneratinib(HKI-272)の安全性、許容性および薬理動態(Molecular target therapy　Safety, tolerability, and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors). 日本癌学会総会記事 2010.08.01

渡邉利泰、末永光邦、久保木泰利、市村崇、川添悦昌、野崎明、大場大、高木浩一、尾阪将人、小倉真理子、篠崎英司、松阪諭、陳頸松、水沼信之、畠清彦. 大腸癌患者におけるBevacizumabの投与規定因子とリスク. 第8回日本臨床腫瘍学会 2010.03 東京

河添悦昌・篠崎英司・細永真理・久保木恭利・市村崇・渡邊利康・大場大・高木浩一・尾阪将人・小倉真理子・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. FOLFOX療法による脾腫が血小板減少および肝酸素に与える影響. 第8回日本臨床腫瘍学会 2010.03 東京

朝井洋晶・篠崎英司・水沼信之・渡邊利康・野崎明・久保木恭利・市村崇・高木浩一・尾阪将人・小倉真理子・末永光邦・松阪諭・陳勁松・畠清彦. cetuximab　併用療法での奏効は治療成功期間を延長する〜再発・転移大腸癌72症例の後方視的解析より〜. 第8回日本臨床腫瘍学会 2010.03 東京

篠崎英司・水沼信之・朝井洋晶・渡邊利康・野崎明・松阪諭・末永光邦・陳勁松・小倉真理子・尾阪将人・久保木恭利・高木浩一・市村崇・畠清彦. cetuximabの治療を受けた大腸癌患者における血清Mgの早期低下は病勢コントロールと相関する可能性. 第8回日本臨床腫瘍学会 2010.03 東京

松阪諭・三嶋雄二・水沼信之・末永光邦・篠崎英司・陳勁松・小倉真理子・尾阪将人・高木浩一・渡邊利康・野崎明・大場大・河添悦昌・照井康仁・畠清彦. Bevacizumabに対するバイオマーカーはCEPおよび,CXCR4+CEC である. 第8回日本臨床腫瘍学会 2010.03 東京

渡邊利泰・篠崎英司・朝井洋昌・久保木恭利・大戸雅史・河添悦昌・野崎明・高木浩一・尾阪将人・小倉真理子・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. 高齢者ではCetuximabのさ瘡洋皮疹が軽くなる可能性がある. 第8回日本臨床腫瘍学会 2010.03 東京

小倉真理子・松阪諭・久保木恭利・市村崇・渡邊利泰・高木浩一・野崎明・尾阪将人・篠崎英司・末永光邦・陳勁松・水沼信之・畠清彦. 進行再発大腸癌に対するFOLFOX4療法の治療成績. 8回日本臨床腫瘍学会 2010.03 東京

大場大・陳勁松・久保木恭利・市村崇・河添悦昌・渡邊利泰・服部正也・高木浩一・尾阪将人・小倉真理子・篠崎英司・末永光邦・松阪諭・水沼信之・畠清彦. 進行胃癌2次化学療法におけるirinotecan治療の意義. 第8回日本臨床腫瘍学会 2010.03 東京

高木浩一・陳勁松・大場大・久保木恭利・大戸雅史・市村崇・河添悦昌・渡邊利泰・尾阪将人・小倉真理子・末永光邦・篠崎英司・松阪諭・水沼信之・畠清彦. S-1耐性胃癌に対するパクリタキセル療法の有効性. 第8回日本臨床腫瘍学会 2010.03 東京

久保木恭利・篠崎英司・市村崇・尾阪将人・大場大・小倉真理子・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. 進行再発胃癌患者におけるCDDPの外来投与の規制因子は消化器毒性である. 第8回日本臨床腫瘍学会 2010.03 東京

陳勁松・吉本和仁・水沼信之・松阪諭・篠崎英司・末永光邦・小倉真理子・尾阪将人・久保木恭利・市村崇・高木浩一・野崎明・渡邊利泰・畠清彦. 胃がん原発巣の化学療法効果判定におけるCTと内視鏡の比較. 第8回日本臨床腫瘍学会 2010.03 東京

大戸雅史・篠崎英司・久保木恭利・市村崇・渡邊利康・高木浩一・尾阪将人・小倉真理子・末永邦光・松阪諭・陳勁松・水沼信之・畠清彦・山本智理子. 食道癌の根治的化学療法における効果測因子としての血清p53抗体の意義. 第8回日本臨床腫瘍学会 2010.03 東京

尾阪将人・久保木恭利・市村崇・河添悦晶・渡邊利康・高木浩一・大場大・小倉真理子・篠崎英司・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. Imatinib投与後、根治療可能なPR症例ではいつ手術を行うべきか?imatinib投与39例の後方視的毛解析より. 第8回日本臨床腫瘍学会 2010.03 東京

水沼信之・篠崎英司・末永光邦・松阪諭・久保木恭利・野崎明・高木浩一・渡邊利康・河添悦昌・畠清彦. 大腸癌に対する化学療法、癌研有明病院でのレトロスペクテイブ的解析. 第8回日本臨床腫瘍学会 2010.03 東京

S. Matsusaka, N. Mizunuma, M. Suenaga, E. Shinozaki, K. Takagi, K. Chin, Y. Mishima, Y. Terui, K. Hatake. Are circulating tumor cells (CTC) and EGFR status of CTC useful as a surrogate marker for determining response to cetuximab in metastatic colorectal cancer?. ASCO-GI 2010.01 SF, US

K. Yoshimoto, K. Chin, H. Yoshimatsu, T. Ichimura, M. Ozaka, M. Ogura, M. Suenaga, E. Shinozaki, S. Matsuzaka, N. Mizunuma, K. Hatake. Comparison of evaluation with endoscopy and CT for primary lesions of the advanced gastric cancer.. ASCO-GI 2010.01 SF, US

E. Shinozaki, N. Mizunuma, H. Asai, T. Watanabe, A. Nozaki, S. Matsusaka, M. Suenaga, K. Hatake. Correlation of early serum magnesium reduction with disease control in metastatic colorectal cancer treated with cetuximab. ASCO-GI 2010.01 SF, US

布施　望、末永　光邦、山口　達郎、松本　寛、水沼　信之、土井　俊彦、畠　清彦、大津　敦　FOLFIRI+BV臨床試験共同研究グループ. 初回治療の進行・再発結腸・直腸癌に対するFOLFIRI+ベバシズマブ（BV）療法の初期安全性及び薬物相互作用の検討. 第7回日本臨床腫瘍学会 2009.03 名古屋

久保木恭利、篠崎英司、尾阪将人、小倉真理子、末永光邦、松阪諭、陳頸松、水沼信之、畠清彦. 進行・再発胃癌に対するS-1/CDDP療法のCDDP外来投与の安全性後方視的解析. 第7回日本臨床腫瘍学会 2009.03 名古屋

野崎明、篠崎英司、、渡邊利泰、高木浩一、西陽子、植木　信江、小坂　泰二郎、尾阪将人、小倉真理子、松阪諭、末永光邦、陳頸松、水沼信之、畠清彦、山本智理子. 結腸・直腸癌における免疫組織化学腺食によるEGFR偽陰性をどう取り扱うか？. 第7回日本臨床腫瘍学会 2009.03 名古屋

尾阪将人、松阪諭、久保木恭利、渡邊利泰、野崎明、西陽子、高木浩一、小倉真理子、篠崎英司、末永光邦、陳頸松、水沼信之、畠清彦. 実臨床におけるFOLFOX耐性後、２次治療としてのFOLFIRI療法の治療成績. 第7回日本臨床腫瘍学会 2009.03 名古屋

西　陽子、末永　光邦、水沼　信之、篠崎　英司、松阪　諭、陳　勁松、久保木　泰利、野崎　明、尾阪　将人、高木　浩一、渡邊　利泰、植木　信江、小坂　泰二郎、小倉　真理子、畠　清彦. Bevacizumab（Bev）／FOLFIRI併用療法の進行・再発結腸直腸癌に対する安全性と有効性. 第7回日本臨床腫瘍学会 2009.03 名古屋

Suenaga Mitsukuni, Mizunuma Nobuyuki, Chin Keisho, Matsusaka Satoshi, Shinozaki Eiji, Oya Masatoshi, Ueno Masashi, Yamaguchi Toshiharu, Muto Tetsuichiro, Konishi Fumio, Hatake Kiyohiko. 単施設での小腸腺癌に対する化学療法(Chemotherapy for Small-Bowel Adenocarcinoma at a Single Institution). Surgery Today 2009.01.01

M. Suenaga, N. Mizunuma, E. Shinozaki, S. Matsusaka, Y. Kuboki, K. Kobayashi, K. Chin, Y. Fujiwara, K. Matsueda, K. Hatake.. Anticoagulant therapy against venous thromboembolism detected by Doppler ultrasound imaging in patients treated with bevacizumab.. ASCO Gastrointestinal Cancers Symposium 2009.01

小林心、末永光邦、篠崎英司、松阪諭、陳頸松、久保木泰利、市村崇、尾阪将人、小倉真理子、松田正典、藤原良将、松枝清、小野寺久、水沼信之、畠清彦. Bevacizumabを用いた大腸がん化学療法前後に生じた静脈血栓症に対するマネージメント. 第6回日本臨床腫瘍学会 2008.03 福岡

篠崎英司、陳頸松、小林心、久保木泰利、市村崇、尾阪将人、松田正典、小倉真理子、、末永光邦、松阪諭、水沼信之、畠清彦. 消化器がん化学療法中の緊急入院に関する後方視的解析. 第6回日本臨床腫瘍学会 2008.03 福岡

尾阪将人,篠崎英司、小林心、久保木泰利、市村崇、松田正典、小倉真理子、陳頸松、末永光邦、松阪諭、水沼信之、畠清彦. FOLFOX療法によ利Complete Responseが得られた進行・転移性結腸直腸癌の後方視的臨床病理学的解析. 第6回日本臨床腫瘍学会 2008.03 福岡

市村崇、陳頸松、小林心、尾阪将人、久保木泰利、小倉真理子、松田正典、末永光邦、松阪諭、水沼信之、畠清彦. 切除不能・進行胃癌の化学療法中に合併した出血、穿孔、血栓症例. 第6回日本臨床腫瘍学会 2008.03 福岡

M. Suenaga, N. Mizunuma, E. Shinozaki, S. Matsusaka, K. Chin, K. Kobayashi, Y. Kuboki, Y. Fujiwara, K. Matsueda, K. Hatake.. Doppler ultrasound imaging in management of venous thromboembolic events in patients treated with chemotherapy and bevacizumab.. ASCO Gastrointestinal Cancers Symposium 2008.01

末永　光邦. 合格のためのサマリーレポートと試験の実際. 日本臨床腫瘍学会第９回教育セミナーAセッション　ランチョンセミナー 2007.08.19 パシフィコ横浜　アネックスホール

松阪 諭, 水沼 信之, 照井 康仁, 三嶋 雄二, 陳 勁松, 末永 光邦, 篠崎 英司, 小倉 真理子, 松田 正典, 市村 崇, 久保木 泰利, 畠 清彦. 転移性大腸癌患者に対する化学療法中の末梢循環癌細胞(Circulating Tumor Cells during Chemotherapy of Metastatic Colorectal Cancer Patients). 日本癌学会総会記事 2007.08.01

松田正典、松阪諭、庄司大悟、渡邊知映、久保木泰利、市村崇、小倉真理子、末永光邦、陳頸松、水沼信之、畠清彦. FOLFOX療法による末梢神経障害の回復の解析. 第5回日本臨床腫瘍学会 2007.03 札幌

久保木泰利、畠清彦、水沼信之、陳頸松、松阪諭、松田正典、末永光邦、小倉真理子、市村崇、庄司大悟、渡邊知映. 高齢者進行・再発大腸癌に対するFOLFOX4療法の安全性について. 2007.03 札幌

小倉真理子、陳頸松、市村崇、久保木泰利、松田正典、末永光邦、松阪諭、水沼信之、畠清彦. 胃癌大量腹水貯留症例に対する全身化学療法についての検討. 第5回日本臨床腫瘍学会 2007.03 札幌

市村崇、陳頸松、久保木泰利、小倉真理子、松田正典、末永光邦、松阪諭、水沼信之、渡邊知映、畠清彦. 高齢者切除不能進行・再発胃癌に対する全身化学療法. 第5回日本臨床腫瘍学会 2007.03 札幌

松阪諭、水沼信之、庄司大悟、渡邊知映、久保木泰利、市村崇、小倉真理子、松田正典、末永光邦、陳頸松、畠清彦. 進行再発大腸癌患者に対するFOLFOX療法後FOLFIRI療法. 第5回日本臨床腫瘍学会 2007.03 札幌

Suenaga Mitsukuni, Oya Masatoshi, Ueno Masashi, Yamamoto Jyunji, Yamaguchi Toshiharu, Mizunuma Nobuyuki, Hatake Kiyohiko, Kato Yo, Muto Tetsuichiro. パジェット様進展を伴った肛門管癌　症例報告(Anal Canal Carcinoma with Pagetoid Spread: Report of a Case). Surgery Today 2006.07.01

庄司大悟、三嶋裕子、篠崎英司、末永光邦、宇良敬、横山雅大、照井康仁、水沼信之、、陳頸松、高橋俊二、伊藤良則、畠清彦. 外来化学療法処方におけるリスクマネジメント業務. 第3回日本臨床腫瘍学会 2005.03.01 横浜

篠崎英司、水沼信之、庄司大悟、陳頸松、末永光邦、宇良敬、大矢雅敏、上野雅資、小口正彦、山口俊晴、武藤徹一郎、畠清彦. 進行下部直腸癌に対する術前放射線化学療法・第II相試験における術後補助化学療法の安全性の検討. 第3回日本臨床腫瘍学会 2005.03.01 横浜

斉藤　良太、大山　繁和、末永　光邦、細井則人、竹林隆介、山口　俊晴. 胃癌術前TS-1/CDDP併用療法におけるリンパ節治療効果とＣＴ所見の変化について. 第76回日本胃癌学会総会 2004.03.03 米子

末永　光邦、大山繁和、佐藤貴弘、斉藤良太、細井則人、山口俊晴、武藤徹一郎、加藤洋. 残胃の癌における空腸間膜リンパ節転移の検討. 第76回日本胃癌学会総会 2004.03.01 米子

大山繁和、竹林隆介、斉藤良太、末永光邦、椿雅光、瀬戸泰之、馬場哲、陳頸松、薄井明子、山口俊晴. 胃癌化学療法のセーフティーマネージメント. 第76回日本胃癌学会総会 2004.03.01 米子

佐藤貴弘、大山繁和、山口俊晴、瀬戸泰之、末永光邦、上野雅資、大矢雅敏、加藤洋、武藤　徹一郎. 腹部における胃spindle cell tumorの位置付け. 第76回日本胃癌学会総会 2004.03.01

小菅崇之、大山　繁和、斉藤良太、末永光邦、細井則人、山口俊晴. 胃癌術前TS-1/CDDP併用療法にて組織学的CRが得られた進行胃癌の一例. 第76回日本胃癌学会総会 2004.03.01 米子

竹林隆介、大山繁和、末永光邦、斉藤良太、山口俊晴. 総肝動脈を合併切除し、肝外側区域切除膵頭十二指腸切除にて根治切除出来た進行胃癌の一例. 第76回日本胃癌学会総会 2004.03.01

末永光邦、大矢雅敏、上野雅資、畦倉薫，佐藤貴弘、 大山繁和，山口俊晴，武藤徹一郎，有賀明子、山田恵子、河野敦、木下博勝，加藤洋. 直腸癌の直腸間膜内リンパ節転移に関する造影CTと高解像度MRI、注腸造影の術前診断能の比較. 第６０回大腸癌研究会 2004.01.01

上野雅資、大矢雅敏、畦倉薫，末永光邦、佐藤貴弘、 山口俊晴、武藤徹一郎. 腹腔鏡下手術におけるリンパ節郭清の程度に関する検討. 第６０回大腸癌研究会 2004.01.01

Suenaga Mitsukuni, Ohta Kei-ichiro, Toguchi Masataka, Sato Takahiro, Ohyama Shigekazu, Yamaguchi Toshiharu, Muto Tetsuichiro, Yanagisawa Akio, Kato Yo. MALT型リンパ腫領域に発生した胃表現型および腸表現型の高分化型衝突腺癌(Colliding gastric and intestinal phenotype well-differentiated adenocarcinoma of the stomach developing in an area of MALT-type lymphoma). Gastric Cancer 2003.12.01

佐藤貴弘、上野雅資、大矢雅敏、畦倉薫、太田博俊、末永光邦、山本順司、山口俊晴、細井則人、斉藤良太、武藤徹一郎. 大腸GISTの切除症例の検討. 第５８回日本大腸肛門病学会総会 2003.11.01 名古屋

佐藤貴弘、大山繁和、上野雅資、大矢雅敏、畦倉薫、山口俊晴、瀬戸泰之、末永光邦、細井則人、山田和彦、斉藤良太、古賀倫太郎、阪本良弘、山本順司、武藤徹一郎. 左門脈の５例. 第７回臨床解剖研究会 2003.09.01 横浜

Sato T, Ohyama S,Nagano H,Suenaga M,Yamaguchi T,Muto T. Surgical treatment for gastric lymphoma in cancer institute hospital in Japan. 5th international gastric cancer congress 2003.05.01 Roma

Suenaga M, Ohta K, Sato T, Hosoi N, Ohyama S, Yamaguchi T, Yanagisawa A, Kato Y.. Colliding gastric and intestinal-type well differentiated adenocarcinomas of the stomach an area typically characterized by MALT-type lymphoma.. 5th international gastric cancer congress. 2003.05

渡邉　利泰、末永光邦、水沼　信之、宇良　敬、陳　頸松、畠　清彦. 当院におけるFOLFOX4療法による末梢神経障害の検討. 第4回日本臨床腫瘍学会 2003.03.18 大阪

永野秀樹、大山繁和、大平寛典、末永光邦、佐藤貴弘、太田恵一郎、山口俊晴、武藤徹一郎. EMR断端陽性例の手術適応について. 第７５回日本胃癌学会総会 2003.02.01 東京

細井則人、大山繁和、佐藤貴弘、末永光邦、大平寛典、太田恵一郎、山口俊晴、奥村栄、中川健、武藤徹一郎. 胃癌術後の肺転移再発に外科切除例の検討. 第７５回日本胃癌学会総会 2003.02.01 東京

佐藤貴弘、大山繁和、永野秀樹、大平寛典、末永光邦、太田恵一郎、山口俊晴、武藤徹一郎、陳頸松、高橋俊二、小口正彦. 当院に於ける胃悪性リンパ腫の治療の近況. 第７５回日本胃癌学会総会 2003.02.01 東京

太田恵一郎、末永光邦、大山繁和、松原敏樹、太田博俊、山口俊晴、武藤徹一郎、中島聰總. 胃癌の腹腔洗浄細胞診の意義と陽性症例に対する治療. 第75回日本胃癌学会総会 2003.02.01 東京

永野秀樹、大山繁和、大平寛典、末永光邦、佐藤貴弘、太田恵一郎、山口俊晴、武藤徹一郎. 胃癌機能温存手術後のQOL評価：患者さんからみたQOL評価. 第７５回日本胃癌学会総会 2003.02.01 東京

佐藤貴弘、大山繁和、永野秀樹、大平寛典、末永光邦、吉田愛、中川彩、太田恵一郎、松原敏樹、山口俊晴、武藤徹一郎、山尾剛一、高橋俊二、小口正彦. 当院に於ける胃悪性リンパ腫の治療. 第３２回胃外科・術後障害研究会 2002.12.01 横浜パシフィコ

末永光邦、太田恵一郎、大平寛典、永野秀樹、佐藤貴弘、大山繁和、山口俊晴. 胃癌術後の骨代謝障害発現について. 第32回胃外科・術後障害研究会 2002.12.01 横浜

大平寛典、大山繁和、末永光邦、永野秀樹、細井則人、佐藤貴弘、太田恵一郎、松原敏樹、太田博俊、山口俊晴. 幽門保存胃切除術のピットフォール. 第32回胃外科・術後障害研究会 2002.12.01 横浜

青山　慧, 加納　嘉人, 末永　光邦, 池田　貞勝, 佐藤　信吾, 森　毅彦. 腫瘍内科専門医の育成に関する、新専門医制度を見据えた本学の取り組み. 第21回日本臨床腫瘍学会学術集会 2024.02.23

青山慧、加納嘉人、末永光邦、池田貞勝、 佐藤信吾、森毅彦. 腫瘍内科専門医の育成に関する、新専門医制度 を念頭に置いた本学の取り組み. 第21 回日本臨床腫瘍学会学術集会 2024.02.22 名古屋国際会議場

山田 岳史, 松橋 延壽, 平田 敬治, 永坂 岳司, 中村 有貴, 坂本 一博, 幸田 圭史, 平松 和洋, 松岡 宏, 倉持 英和, 石田 秀行, 片岡 幸三, 横溝 肇, 賀川 義規, 末永 光邦, 太田 竜, 松田 明久, 園田 寛道, 吉田 寛, 高橋 孝夫. ゲノム医療の最前線　RAS/BRAF空間的不均一性が抗EGFR抗体の効果に与える影響. 日本大腸肛門病学会雑誌 2023.09.01

石川 氷介, 森川 亮, 野地 理夏, 本村 鷹太朗, 加納 嘉人, 末永 光邦. 進行胃癌薬物療法中に六君子湯による急性アルドステロン症を発症した1例. 日本内科学会関東地方会 2023.03.01

末永 光邦, 山内 慎一, 佐藤 雄哉, 徳永 正則, 植竹 宏之, 絹笠 祐介. 化学療法に起因する消化管関連合併症に対する治療戦略　化学療法中の消化器関連有害事象に対する治療アプローチ. 日本腹部救急医学会雑誌 2022.02.01

Matsumiya Yuriko, Suenaga Mitsukuni, Ishikawa Toshiaki, Hanaoka Marie, Iwata Noriko, Masuda Taiki, Yamauchi Shinichi, Tokunaga Masanori, Kinugasa Yusuke. Clinical significance of Bacteroides fragilis as potential prognostic factor in colorectal cancer patients. 2022 ASCO Gastrointestinal Cancers Symposium 2022.02.01

Suenaga Mitsukuni, Yamauchi Shinichi, Masuda Taiki, Hanaoka Marie, Iwata Noriko, Sato Yuya, Tomii Chiharu, Tokunaga Masanori, Kinugasa Yusuke. COVID-19 vaccination in gastrointestinal cancer patients receiving chemotherapy: A single institute experience. 2022 ASCO Gastrointestinal Cancers Symposium 2022.02.01

松宮由利子、末永光邦、角田龍太、岩田乃理子、増田大機、山内慎一、松山貴俊、徳永正則、石川敏昭、絹笠祐介. 大腸癌術後患者におけるBacteroides fragilisと予後の検討. 第76回日本消化器外科学会総会 2021.07.08 WEB

伊沢 由紀子, 中山 厳馬, 陳 頸松, 篠崎 英司, 高張 大亮, 末永 光邦, 大木 暁, 小倉 真理子, 大隅 寛木, 鈴木 健, 熊谷 厚志, 山口 研成. 切除不能進行・再発胃がんの全身化学療法の継続性・治療効果と栄養指標の関連の検討. 日本癌治療学会学術集会抄録集 2019.10.01

鈴木 幹子, 山田 沙織, 西 かおり, 川上 優生, 坪井 望美, 大野 愛, 馬場 誠一郎, 市橋 和明, 晝間 典子, 望月 俊明, 山本 豊, 尾松 公平, 尾阪 将人, 太田 弓子, 大隅 寛木, 中山 厳馬, 若槻 尊, 小倉 真理子, 高張 大亮, 篠崎 英司, 末永 光邦, 陳 勁松, 山口 研成, 市村 崇. 大量腹水を有する切除不能進行・再発癌患者に対する全身化学療法併用腹水濾過濃縮再静注法(CART)の安全性と有効性. 日本臨床工学技士会会誌 2018.09.01

陳 勁松, 小倉 真理子, 篠崎 英司, 市村 崇, 若槻 尊, 末永 光邦, 松島 知宏, 中山 厳馬, 大隅 寛木, 太田 弓子, 山口 研成. 80歳以上の転移進行胃癌症例へのG8 screening toolによる高齢者評価の意義. 日本胃癌学会総会記事 2018.03.01

牛田 雄太, 陳 勁松, 末永 光邦, 布部 創也, 篠崎 英司, 高張 大亮, 小倉 真理子, 市村 崇, 若槻 尊, 山口 研成. Conversion therapyにおける術後TS-1内服療法と生存期間についての検討. 日本胃癌学会総会記事 2018.03.01

市村 崇, 陳 勁松, 高張 大亮, 小倉 真理子, 篠崎 英司, 末永 光邦, 若槻 尊, 大隅 寛木, 中山 厳馬, 太田 弓子, 山口 研成. 高度腹水を有する進行胃癌に対する腹水濾過濃縮再静注法(CART)併用化学療法についての後方視的解析. 日本胃癌学会総会記事 2018.03.01

本間 理, 若槻 尊, 大隅 寛木, 松島 知広, 中山 厳馬, 市村 崇, 小倉 真理子, 尾阪 将, 高張 大亮, 末永 光邦, 篠崎 英司, 陳 勁松, 山口 研成. HER2陽性切除不能進行/再発胃癌におけるCapecitabineとPPIの相互作用についての検討. 日本癌治療学会学術集会抄録集 2017.10.01

八木 秀祐, 若槻 尊, 山本 智理子, 陳 勁松, 末永 光邦, 篠崎 英司, 高張 大亮, 小倉 真理子, 市村 崇, 尾阪 将人, 中山 厳馬, 松島 知広, 大隅 寛木, 石川 雄一, 山口 研成. HER2陽性胃癌における生検検体を用いた腫瘍内不均一性の臨床的意義. 日本癌治療学会学術集会抄録集 2017.10.01

野々宮 悠真, 横川 貴志, 川上 和宜, 杉田 一男, 瀧口 友美, 杉崎 崇人, 青山 剛, 鈴木 賢一, 若槻 尊, 末永 光邦, 山口 研成, 杉本 芳一, 濱 敏弘. 大腸　分子標的薬治療の現状　レゴラフェニブにおける手足症候群に関する後ろ向き観察研究. 日本癌治療学会学術集会抄録集 2016.10.01

市村 崇, 粂川 陽祐, 陳 頸松, 高張 大亮, 小倉 真理子, 尾阪 将人, 末永 光邦, 篠崎 英司, 水沼 信之. 切除不能・再発胃癌に対するSOX療法(オキサリプラチン130mg/m2)の後方視的解析. 日本癌治療学会誌 2015.09.01

大隅 寛木, 篠崎 英司, 末永 光邦, 小倉 真理子, 尾阪 将人, 松阪 諭, 陳 勁松, 小西 毅, 秋吉 高志, 藤本 佳也, 長山 聡, 福長 洋介, 上野 雅資, 水沼 信之. 当院における大腸癌stage III症例の術後補助化学療法の変遷. 日本癌治療学会誌 2015.09.01

中山 厳馬, 篠崎 英司, 松島 知広, 若槻 尊, 小倉 真理子, 市村 崇, 尾阪 将人, 高張 大亮, 末永 光邦, 陳 勁松, 水沼 信之. 大腸　大腸がんの包括的ゲノム解析　StageIV大腸癌一次治療におけるRAS/PIK3CA/BRAF遺伝子変異とbevacizumabの治療効果. 日本癌治療学会誌 2015.09.01

向井 俊貴, 秋吉 高志, 上野 雅資, 福長 洋介, 長山 聡, 藤本 佳也, 小西 毅, 五十嵐 正広, 為我井 芳郎, 千野 晶子, 岸原 輝仁, 水沼 信之, 篠崎 英司, 末永 光邦. 80歳以上の高齢者大腸癌に対する治療戦略. 日本大腸肛門病学会雑誌 2015.05.01

末永 光邦, 水沼 信之, 篠崎 英司, 福長 洋介, 秋吉 高志, 長山 聡, 藤本 佳也, 小西 毅, 上野 雅資, 川上 和宜, 横川 貴志, 山口 俊晴. StageII/III結腸癌治癒切除例に対する術後補助化学療法としてのCapecitabine + Oxaliplatin(XELOX)療法のFeasibility試験　ACTOR study. 日本外科学会定期学術集会抄録集 2015.04.01

中山 厳馬, 陳 勁松, 市村 崇, 高張 太亮, 尾阪 将人, 末永 光邦, 篠崎 英司, 水沼 信之. 40歳未満で診断されたStage.4若年性胃がんに対する化学療法の効果. 日本胃癌学会総会記事 2015.03.01

粂川 陽祐, 陳 勁松, 松島 知広, 小倉 真理子, 市村 崇, 高張 大亮, 尾坂 将人, 末永 光邦, 篠崎 英司, 水沼 信之, 横川 貴志, 青山 剛, 加藤 紀香, 長崎 礼子, 横井 麻珠美. 胃癌治療におけるチームビルディング　SOX療法導入のためのチーム医療の取り組み. 日本胃癌学会総会記事 2015.03.01

Mitsukuni Suenaga, Nobuyuki Mizunuma, Eiji Shinozaki, Izuma Nakayama, Takeru Wakatsuki, Masato Ozaka, Yosuke Kumekawa, Mariko Ogura, Keisho Chin, Toshiharu Yamaguchi. Analysis of the Safety of Regorafenib Monotherapy in patients with Metastatic Colorectal Cancer. 第12回日本臨床腫瘍学会学術集会 2014.07.18

杉田 一男, 川上 和宜, 横川 貴志, 前 勇太郎, 戸谷 渡, 萩野 茜, 鈴木 賢一, 末永 光邦, 水沼 信之, 山口 俊晴, 濱 敏弘. レゴラフェニブ服用患者における甲状腺機能低下症の発現頻度と発現時期の調査. 日本癌治療学会誌 2014.06.01

末永　光邦. 大腸癌に対する最近の治療戦略. ¥日本臨床腫瘍薬学会学術大会2014 2014.03.22 幕張

中山 厳馬, 陳 勁松, 若槻 尊, 小倉 真理子, 尾阪 将人, 篠崎 英司, 末永 光邦, 水沼 信之. P0CY1、Stage.4胃がんに対するR1切除後、S-1+CDDP療法の意義. 日本胃癌学会総会記事 2014.03.01

小西 毅, 松阪 諭, 上野 雅資, 福長 洋介, 長山 聡, 藤本 佳也, 秋吉 高志, 水沼 信之, 篠崎 英司, 末永 光邦, 五十嵐 正広, 為我井 芳郎, 浦上 尚之, 千野 晶子, 岸原 輝仁, 山口 俊晴, 畠 清彦, 武藤 徹一郎. 直腸癌に対する術前化学放射線療法が血中遊離癌細胞(CTC)に与える影響に関する検討. 日本大腸肛門病学会雑誌 2014.03.01

川上 和宜, 横川 貴志, 鬼山 彩果, 前 勇太郎, 萩野 茜, 杉田 一男, 町田 昌明, 鈴木 賢一, 末永 光邦, 水沼 信之, 山口 俊晴, 濱 敏弘. XELOX療法におけるカペシタビンの服薬compliance. 日本薬学会年会要旨集 2014.03.01

大隅 寛木, 篠崎 英司, 粂川 陽祐, 小倉 真理子, 尾坂 将人, 末永 光邦, 松阪 諭, 陳 勁松, 水沼 信之, 横山 雅大. Oxaliplatinを含む化学療法中に著明な血小板減少を来した3症例. 癌と化学療法 2013.11.01

横川 貴志, 川上 和宜, 前 勇太郎, 杉田 一男, 渡邉 大至, 鈴木 賢一, 末永 光邦, 水沼 信之, 山口 俊晴, 濱 敏弘. XELOX±ベバシズマブ療法における手足症候群重篤化のリスク因子. 日本癌治療学会誌 2013.09.01

益満 幸一郎, 原田 亜矢, 野田 昌弘, 恵 浩一, 瀬戸山 徹郎, 北薗 正樹, 有留 邦明, 末永 光邦. 当院での腹腔鏡下胆嚢摘出術における現状. 日本消化器外科学会総会 2013.07.01

長山 聡, 末永 光邦, 水沼 伸之, 上野 雅資, 福長 洋介, 藤本 佳也, 小西 毅, 秋吉 高志, 古賀 倫太郎, 齋浦 明夫, 布部 創也, 比企 直樹, 谷村 愼哉, 山田 和彦, 峯 真司, 佐野 武, 山口 俊晴. 術前FOLFOX4+BV療法が著効し、腹腔鏡下で切除し得たMarginally resectable StageIIIb大腸癌の一例. 日本外科学会雑誌 2013.03.01

末永 光邦, 水沼 信之, 吉田 陽一郎, 堀田 司, 的場 周一郎, 篠崎 勝則, 村田 幸平, 佐藤 純人, 吉田 真, 川崎 実. XELOX、XELOX+アバスチン特定使用成績調査　調査結果報告. 日本癌治療学会誌 2012.10.01

松阪 諭, 水沼 信之, 陳 勁松, 末永 光邦, 篠崎 英司, 上野 雅資, 佐野 武, 山口 俊晴. 消化器癌分子標的治療薬における末梢循環血中癌細胞および血管内皮細胞の有用性. 日本癌治療学会誌 2012.10.01

渡邉 利泰, 末永 光邦, 牛込 充則, 塩川 洋之, 栗原 聰元, 小池 淳一, 島田 長人, 船橋 公彦, 中嶋 均, 水沼 信之. 5-FUにより意識障害を伴う高アンモニア血症を呈した3症例. 日本大腸肛門病学会雑誌 2012.09.01

Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, , Masato Ozaka, Mariko Ogura, Keisho Chin, Kiyohiko Hatake, Nobuyuki Mizunuma, ToshiharuYamaguchi. A Phase I /II study of Bi-weekly XELIRI plus bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy (BIXER study): Reports of interim analysis of Phase II part. 第10回日本臨床腫瘍学会学術集会 2012.07.28

陳 勁松, 小倉 真理子, 篠崎 英司, 末永 光邦, 松阪 諭, 久保木 恭利, 高木 浩一, 尾阪 将人, 水沼 信之. 分子標的治療剤　導入後の課題と今後の展望　HER2過剰発現転移進行胃癌に対するtrastuzumab導入後の現状　XPT外来投与の実際. 日本胃癌学会総会記事 2012.02.01

渡邉 利泰, 篠崎 英司, 菊池 由宣, 大原 克仁, 貴島 祥, 高木 浩一, 久保木 恭利, 尾阪 将人, 小倉 真理子, 末永 光邦, 松阪 諭, 陳 勁松, 水沼 信之, 畠 清彦, 瓜田 純久, 杉本 元信. Cetuximab投与でのInfusion related reaction患者においてPanitumumabの投与は安全か?. 日本消化器病学会雑誌 2011.09.01

宇良 敬, 水沼 信之, 仁科 智裕, 安井 久晃, 傳田 忠道, 岩永 一郎, 江崎 泰斗, 西崎 朗, 寺西 寧, 近藤 建, 末永 光邦, 梶原 猛史, 上林 実, 室 圭. FOLFOX不応不耐大腸癌に対するFOLFIRI(CPT-11;180)+bevacizumab(BV)の第II相臨床試験. 日本癌治療学会誌 2011.09.01

末永 光邦, 松阪 諭, 篠崎 英司, 上野 雅資, 山口 俊晴, 水沼 信之. 大腸癌術後補助FOLFOX療法の使用経験. 日本癌治療学会誌 2011.09.01

Suenaga M, Matsusaka S, Mizunuma N, Shinozaki E, Ohhara Y, Kuboki Y, Yamaguchi T, Hatake K. A Phase I/II study of Bi-weekly XELIRI plus bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy（BIXER study）: Reports of Phase I part. 第9回日本臨床腫瘍学会 2011.07.21

松尾 康正, 千野 晶子, 堀内 裕介, 吉澤 奈津子, 今井 瑞香, 岸原 輝仁, 平澤 俊明, 山本 頼正, 土田 知宏, 藤崎 順子, 五十嵐 正広, 尾阪 将人, 篠崎 英司, 末永 光邦, 水沼 信之. EUS-FNAで確定診断後、術前補助化学療法を施行した直腸GISTの1例. Progress of Digestive Endoscopy 2011.06.01

市村 崇, 陳 勁松, 小林 心, 尾阪 将人, 久保木 恭利, 小倉 真理子, 篠崎 英司, 末永 光邦, 松坂 諭, 水沼 信之, 畠 清彦. 切除不能進行・再発胃癌の化学療法中に発症した消化管出血・血栓塞栓症・消化管穿孔症例の後方視的研究. 癌と化学療法 2010.11.01

安井 久晃, 水沼 信之, 傳田 忠道, 室 圭, 高橋 康雄, 西崎 朗, 齊藤 幸夫, 江崎 泰斗, 武田 晃司, 山口 研成, 末永 光邦, 宇良 敬, 津田 政広, 平良 高一, 石窪 力. FOLFOX不応・不耐大腸癌に対するFOLFIRI(CPT-11;180)+bevacizumab(BV)の第II相臨床試験. 日本癌治療学会誌 2010.09.01

末永光邦. 外来化学療法を安全に確実に実施するためのコツ. 第21回日本在宅医療学会、医師・看護師・薬剤師のための外来化学療法実践セミナーin お台場2010 2010.06.13 東京

M. Suenaga, N. Mizunuma, E. Shinozaki, S. Matsusaka, K. Chin, Y Kuboki, T. Watanabe, Y. Fujimoto, M Ueno, H. Kuroyanagi, M. Oya, N. Yamamoto, K. Hatake. Oxaliplatin継続はStage IIIb, IV結腸直腸癌に対する術後補助FOLFOX療法の効果予測因子である. 第8回日本臨床腫瘍学会 2010.03

今田 洋司, 及川 尚子, 末永 光邦, 中本 恵理, 平岡 知子, 水沼 信之, 濱 敏弘. ベバシズマブによる高血圧の降圧剤の検討. 日本薬学会年会要旨集 2009.03.01

松阪 諭, 陳 勁松, 小倉 真理子, 末永 光邦, 篠崎 英司, 水沼 信之, 畠 清彦. 進行・再発胃癌化学療法患者における末梢循環胃癌細胞の意義. 日本胃癌学会総会記事 2009.03.01

末永光邦、水沼信之、篠崎英司、松阪諭、陳勁松、西陽子、久保木恭利、野崎明、尾阪将人、高木浩一、渡邉利泰、植木信江、小坂泰二郎、小倉真理子、畠清彦. Bevacizumab (Bev)／FOLFOX4併用療法の進行・再発結腸直腸癌に対する安全性と有効性. 第7回日本臨床腫瘍学会 2009.03

藤原 良将, 山田 恵子, 山本 弥生, 行澤 斉悟, 松枝 清, 河野 敦, 末永 光邦, 畠 清彦. 高周波超音波検査による、中心静脈ポートに関連する血栓症の評価. 日本医学放射線学会学術集会抄録集 2009.02.01

大矢 雅敏, 斉浦 明夫, 古賀 倫太郎, 名取 健, 藤本 佳也, 黒柳 洋弥, 上野 雅資, 秋吉 高志, 小西 毅, 福田 明輝, 末永 光邦, 水沼 信之, 山本 順司. 大腸癌同時性肝転移の切除成績　術前治療の有用性. 日本大腸肛門病学会雑誌 2008.09.01

福田 明輝, 大矢 雅敏, 黒柳 洋弥, 上野 雅資, 藤本 佳也, 秋吉 高志, 小西 毅, 末永 光邦, 水沼 信之, 篠崎 英司, 松阪 諭, 奥村 栄. 大腸癌肺転移症例の検討. 日本大腸肛門病学会雑誌 2008.09.01

神杉 香代子, 今田 洋司, 庄司 大悟, 横川 貴志, 中本 恵理, 川上 和宜, 縄野 一美, 平田 良美, 小川 恵, 松阪 諭, 篠崎 英司, 末永 光邦, 水沼 信之, 畠 清彦, 濱 敏弘. FOLFIRI療法の有害事象調査に基づいた患者向け説明書の作成. 日本薬学会年会要旨集 2008.03.01

大矢 雅敏, 上野 雅資, 黒柳 洋弥, 藤本 佳也, 秋吉 高志, 小川 京子, 山口 俊晴, 武藤 徹一郎, 五十嵐 正広, 浦上 尚之, 松阪 諭, 末永 光邦, 水沼 信之. 術前FOLFOX療法後に原発巣切除を試みた進行大腸癌症例の手術経験. 日本大腸肛門病学会雑誌 2007.09.01

末永光邦、水沼信之、松阪諭、久保木泰利、市村崇、松田正典、小倉真理子、陳頸松、庄司大悟、畠清彦. FOLFOX4療法におけるアレルギー反応の臨床学的特徴と予防法の効果. 第5回日本臨床腫瘍学会 2007.03

末永光邦、水沼　信之、宇良　敬、渡邉　利泰、五月女　隆、陳　頸松、庄司　大悟、畠　清彦. FOLFOX療法によるアレルギー性反応に対する予防法の検討. 第4回日本臨床腫瘍学会 2006.03

庄司 大悟, 水津 ちづる, 渡邊 知映, 水沼 信之, 陳 勁松, 高橋 俊二, 伊藤 良則, 徳留 なほみ, 末永 光邦, 宇良 敬, 畠 清彦. 固形がん化学療法施行患者における貧血発現状況に関する調査研究. 血液・腫瘍科 2006.02.01

武田 信子, 山田 陽子, 末永 光邦. ストーマ造設後の5ヵ月後に腸管虚血によるストーマ壊死を発生した1例. 日本ストーマリハビリテーション学会誌 2005.12.01

末永光邦、水沼信之、篠崎英司、上野雅資、大矢雅敏、宇良敬、陳頸松、山口俊晴、武藤徹一郎、畠清彦. 当院における進行再発小腸癌に対する化学療法. 第3回日本臨床腫瘍学会 2005.03

末永 光邦, 大山 繁和, 佐藤 貴弘, 細井 則人, 斉藤 良太, 山口 俊晴, 武藤 徹一郎. 上部胃癌における脾門リンパ節郭清について. 日本消化器外科学会雑誌 2004.10.01

佐藤 貴弘, 大山 繁和, 上野 雅資, 大矢 雅敏, 畦倉 薫, 山口 俊晴, 瀬戸 泰之, 末永 光邦, 細井 則人, 山田 和彦, 齋藤 良太, 古賀 倫太郎, 阪本 良弘, 山本 順司, 武藤 徹一郎. 当科で経験した左門脈症例. 日本消化器外科学会雑誌 2004.10.01

斉藤 良太, 大山 繁和, 末永 光邦, 細井 則人, 山口 俊晴. 噴門側胃切除術食道胃吻合における後壁吻合の有用性について. 日本消化器外科学会雑誌 2004.10.01

大山 繁和, 末永 光邦, 斎藤 良太, 永野 秀樹, 佐藤 貴弘, 山田 和彦, 瀬戸 泰之, 山口 俊晴. 食道浸潤胃癌の至適郭清範囲の検討　開胸症例の解析. 日本消化器外科学会雑誌 2004.10.01

陳 勁松, 水沼 信之, 石山 晃世志, 保坂 尚志, 末永 光邦, 篠崎 英司, 畠 清彦. 切除不能/再発胃癌に対するPaclitaxel(PAC)+Methotrexate(MTX)+5-Fluoruracil(FU)(PMF)併用療法第I相試験. 日本癌治療学会誌 2004.09.01

畦倉 薫, 末永 光邦, 斉浦 明夫, 瀬戸 泰之, 上野 雅資, 関 誠, 大矢 雅俊, 山本 順司, 山口 俊晴, 武藤 徹一郎. 下部直腸sm(〜mp浅層)癌に対する適正手術　sentinel node conceptからのアプローチ. 日本消化器外科学会雑誌 2004.07.01

佐藤 貴弘, 上野 雅資, 大矢 雅敏, 畦倉 薫, 山口 俊晴, 末永 光邦, 武藤 徹一郎, 加藤 洋. 術前評価の困難であったLST由来進行大腸癌の1例. 日本消化器外科学会雑誌 2004.07.01

末永 光邦, 大矢 雅敏, 上野 雅資, 畦倉 薫, 大山 繁和, 佐藤 貴弘, 山口 俊晴, 武藤 徹一郎, 河野 敦, 加藤 洋. 直腸癌の直腸間膜内リンパ節転移診断における造影CTと高解像度MRI,注腸造影の比較. 日本消化器外科学会雑誌 2004.07.01

畦倉 薫, 末永 光邦, 斉浦 明夫, 瀬戸 泰之, 上野 雅資, 関 誠, 大矢 雅俊, 山本 順司, 山口 俊晴, 武藤 徹一郎. 下部直腸sm(～mp浅層)癌に対する適正手術　sentinel node conceptからのアプローチ. 日本消化器外科学会雑誌 2004.07.01

末永 光邦, 大矢 雅敏, 上野 雅資, 畦倉 薫, 佐藤 貴弘, 大山 繁和, 山口 俊晴, 武藤 徹一郎, 有賀 明子, 山田 恵子, 河野 敦, 木下 博勝, 加藤 洋. 直腸癌の直腸間膜内リンパ節転移に関する造影CTと高解像度MRI,注腸造影の術前診断能の比較. 日本大腸肛門病学会雑誌 2004.06.01

上野 雅資, 大矢 雅敏, 畦倉 薫, 末永 光邦, 佐藤 貴弘, 山口 俊晴, 武藤 徹一郎. 腹腔鏡下手術におけるリンパ節郭清の程度の関する検討. 日本大腸肛門病学会雑誌 2004.06.01

佐藤 貴弘, 上野 雅資, 大矢 雅敏, 畦倉 薫, 山口 俊晴, 大山 繁和, 瀬戸 泰之, 山田 和彦, 永野 秀樹, 末永 光邦, 細井 則人, 齋藤 良太, 山本 順司, 武藤 徹一郎, 荷見 勝彦, 福井 巌, 川口 智義, 藤田 力也, 加藤 洋. 十二指腸・小腸・大腸・後腹膜spindle cell tumor切除症例の検討. 日本外科学会雑誌 2004.03.01

末永 光邦, 大矢 雅敏, 大山 繁和, 上野 雅資, 畦倉 薫, 瀬戸 泰之, 山本 順司, 佐藤 貴弘, 斉藤 良太, 山口 俊晴, 武藤 徹一郎, 有賀 明子, 山田 恵子, 河野 敦. 直腸癌のリンパ節転移における造影CTと高解像度MRIの術前診断能の比較. 日本外科学会雑誌 2004.03.01

斉藤 良太, 大山 繁和, 末永 光邦, 細井 則人, 佐藤 貴之, 山口 俊晴, 武藤 徹一郎. 進行胃癌に対する術前TS-1/CDDP併用療法の副作用と奏効率の関係について. 日本外科学会雑誌 2004.03.01

大山 繁和, 末永 光邦, 斎藤 良太, 佐藤 貴弘, 瀬戸 泰之, 大矢 雅俊, 山本 順司, 山口 俊晴. 進行胃癌に対する術前化学療法phase II studyの治療成績からみた術前化学療法の適応について. 日本外科学会雑誌 2004.03.01

末永 光邦, 大矢 雅敏, 上野 雅資, 佐藤 貴弘, 細井 則人, 斉藤 良太, 畦倉 薫, 太田 博俊, 山口 俊晴, 武藤 徹一郎. 肛門周囲皮膚にPagetoid spreadを来たした直腸sm癌の1例. 日本大腸肛門病学会雑誌 2003.11.01

末永光邦、大山繁和、斉藤良太、佐藤貴弘、細井則人、山口俊晴. 上部胃癌における脾門部リンパ節郭清について. 第33回胃外科・術後障害研究会 2003.11

佐藤 貴弘, 上野 雅資, 大矢 雅敏, 太田 博俊, 畦倉 薫, 大山 繁和, 瀬戸 泰之, 山口 俊晴, 阪本 良弘, 山本 順司, 末永 光邦, 細井 則人, 齋藤 良太, 武藤 徹一郎. 小腸・大腸GIST切除例の検討. 日本臨床外科学会雑誌 2003.10.01

大山 繁和, 末永 光邦, 細井 則人, 上野 雅資, 大矢 雅敏, 山本 順司, 山口 俊晴, 武藤 徹一郎. 胃分節(横断)切除術の長期成績. 日本臨床外科学会雑誌 2003.10.01

細井 則人, 大山 繁和, 末永 光邦, 瀬戸 泰之, 太田 惠一郎, 山口 俊晴, 武藤 徹一郎. 高度進行胃癌に対する術前TS-1/CDDP併用療法の検討. 日本臨床外科学会雑誌 2003.10.01

佐藤 貴弘, 上野 雅資, 大矢 雅敏, 畦倉 薫, 太田 博俊, 末永 光邦, 山本 順司, 山口 俊晴, 細井 則人, 斉藤 良太, 武藤 徹一郎. 大腸GIST切除症例の検討. 日本大腸肛門病学会雑誌 2003.09.01

末永 光邦, 太田 惠一朗, 大平 寛典, 永野 秀樹, 佐藤 貴弘, 大山 繁和, 山口 俊晴. 胃癌術後の骨代謝障害発現について. 日本消化器外科学会雑誌 2003.09.01

佐藤 貴弘, 大山 繁和, 水野 秀樹, 大平 寛典, 末永 光邦, 太田 惠一朗, 山口 俊晴, 武藤 徹一郎, 陳 勁松, 高橋 俊二, 小口 正彦. 当院における胃悪性リンパ腫の治療. 日本消化器外科学会雑誌 2003.09.01

大平 寛典, 大山 繁和, 末永 光邦, 永野 秀樹, 細井 則人, 佐藤 貴弘, 太田 惠一朗, 松原 敏樹, 太田 博俊, 山口 俊晴. 幽門保存胃切除術のピットフォール. 日本消化器外科学会雑誌 2003.09.01

末永光邦、大山繁和、斉藤良太、佐藤貴弘、細井則人、山口俊晴. 術前3D−CTによる血管浸潤の評価. 第７回臨床解剖研究会 2003.09

佐藤 貴弘, 太田 惠一朗, 山口 俊晴, 大山 繁和, 永野 秀樹, 山本 順司, 末永 光邦, 大矢 雅敏, 武藤 徹一郎. Klippel-Trenaunay-Weber症候群に合併した十二指腸潰瘍大量出血の1例. 日本消化器外科学会雑誌 2003.07.01

末永 光邦, 大矢 雅敏, 上野 雅資, 畦倉 薫, 太田 博俊, 大山 繁和, 山口 俊晴, 武藤 徹一郎. 直腸癌症例における注腸造影検査上の仙骨前腔(直腸後腔)の開大. 日本消化器外科学会雑誌 2003.07.01

佐藤 貴弘, 畦倉 薫, 上野 雅資, 太田 惠一朗, 太田 博俊, 大矢 雅敏, 大山 繁和, 大平 寛典, 阪本 良弘, 関 誠, 中川 彩, 二宮 康郎, 永野 秀樹, 細井 則人, 末永 光邦, 山田 和彦, 松原 敏樹, 山本 順司, 山口 俊晴, 武藤 徹一郎, 國土 . 消化器外科領域の脂肪肉腫切除症例の検討. 日本外科学会雑誌 2003.04.01

末永光邦、太田恵一郎、佐藤貴弘、細井則人、大平寛典、永野秀樹、大山繁和、山口俊晴、武藤徹一郎、中島聰總. Krukenberg腫瘍65例の検討. 第75回日本胃癌学会 2003.02

末永光邦、太田恵一郎、山口俊晴、武藤徹一郎. 抗血漿タンパク質抗体による副作用の報告. 2002.12

大平 寛典, 大山 繁和, 末永 光邦, 永野 秀樹, 佐藤 貴弘, 太田 恵一朗, 松原 敏樹, 山口 俊晴, 武藤 徹一郎. 胃癌治癒切除後における他臓器癌に対するフォローアップ法について. 日本臨床外科学会雑誌 2002.10.01

末永 光邦, 太田 惠一朗, 大平 寛典, 永野 秀樹, 佐藤 貴弘, 大山 繁和, 山口 俊晴. 胃癌術後の骨代謝障害の検討. 日本臨床外科学会雑誌 2002.10.01

三枝 伸二, 久保 昌亮, 花園 幸一, 末永 光邦, 福元 俊孝. 腹腔内リンパ節転移を介し胃,膵被膜への浸潤がみられた胸部食道粘膜癌の1例. 鹿児島県臨床外科学会誌 2002.07.01

渋谷 寛, 田畑 峯雄, 溝内 十郎, 大迫 政彦, 黒木 直哉, 門野 潤, 久米村 秀, 末永 光邦, 亀川 寛大, 迫田 晃子. 鈍的外傷による肝外胆管損傷の2例. 日本腹部救急医学会雑誌 2001.08.01

渋谷 寛, 田畑 峯雄, 溝内 十郎, 大迫 政彦, 黒木 直哉, 久米村 秀, 末永 光邦, 亀川 寛大, 迫田 晃子, 迫田 晃郎. 小腸機械的イレウスの手術決定の目安と術式. 日本消化器外科学会雑誌 2001.07.01

末永 光邦, 溝内 十郎, 迫田 晃郎, 田畑 峯雄, 大迫 政彦, 渋谷 寛, 黒木 直哉, 矢野 武志, 永田 耕治. イレウスで発症し高気圧酸素療法後,穿孔性腹膜炎を呈した腸結核合併盲腸癌の1例. 日本腹部救急医学会雑誌 2001.02.01

末永光邦、田畑峯雄、坂元弘人、大迫政彦、亀川寛大、渋谷寛、久米村秀、溝内十郎、迫田晃郎、山口俊一郎、有村敏明. 高気圧酸素療法が無効であった腸閉塞の４例. 第48回鹿児島救急医学会 2000.09

久保 文武, 徳重 正弘, 肝付 兼達, 福留 哲朗, 末永 光邦, 愛甲 孝. 門脈ガス血症を呈した壊死性大腸炎の1例. 日本消化器外科学会雑誌 2000.07.01

末永光邦、久保文武、福留哲朗、徳重正弘、肝付兼達. 内視鏡的に摘出し得た胃内異物の１例. 第47回鹿児島救急医学会 2000.03